

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 February 2001 (15.02.2001)

PCT

(10) International Publication Number
WO 01/11041 A1

(51) International Patent Classification⁷: C12N 15/12, (74) Agents: WEICKMANN, H. et al.; Kopernikusstrasse 9,
C07K 14/495, A61K 38/18 D-81679 München (DE).

(21) International Application Number: PCT/EP00/07600

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 4 August 2000 (04.08.2000)

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

(26) Publication Language: English


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(30) Priority Data:
99115613.4 6 August 1999 (06.08.1999) EP

(71) Applicant (*for all designated States except US*): HY-
GENE AG [CH/CH]; c/o Mäder + Baumgartner Treuhand
AG, Schwanenfelsstrasse 10a, CH-8121 Neuhausen am
Rheinfall (CH).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): HÖTTEN, Gertrud
[DE/DE]; Hölkenskampring 96, D-44625 Herne (DE).
BECHTOLD, Rolf [DE/DE]; Carl-Zuckmayer-Strasse
21, D-69126 Heidelberg (DE). PORHL, Jens [DE/DE];
Bastwaldstrasse 25, D-76707 Hambücken (DE).



WO 01/11041 A1

(54) Title: MONOMERIC PROTEIN OF THE TGF- β FAMILY

(57) Abstract: The present invention is concerned with proteins selected from the members of the TGF- β superfamily, which are monomeric due to substitution or deletion of a cysteine which is responsible for dimer formation. The invention is also concerned with nucleic acids, encoding such monomeric proteins, vectors or host cells containing the nucleic acids as well as with pharmaceutical compositions comprising the proteins or nucleic acids encoding the proteins. The pharmaceutical compositions can be applied advantageously for all indications for which the respective dimeric proteins are useful.

Monomeric Protein of the TGF- β Family**Description**

5

The present invention concerns a biologically active protein from the TGF- β superfamily, wherein this protein remains in monomeric form due to substitution or deletion of a cysteine which is responsible for the dimerization in the wild-type protein. Further the invention concerns a nucleic acid, 10 which codes for a protein according to the invention, an expression vector containing such nucleic acid and a host cell, containing a corresponding nucleic acid or an expression vector, said nucleic acid being suitable for the expression of the protein. The invention also concerns a pharmaceutical composition containing the protein according to the invention or a nucleic acid coding therefor. The use of the pharmaceutical composition according 15 to the invention concerns the prevention or treatment of all conditions which can also be treated with the dimeric form of the corresponding protein.

-
- 20 Many growth factors from the TGF- β superfamily (Kingsley, Genes and Development 8, 133-146 (1994) as well as the references cited therein) are relevant for a wide range of medical treatment methods and applications which in particular concern promotion of cell proliferation and tissue formation, including wound healing and tissue reproduction. Such growth 25 factors in particular comprise members of the TGF- β (transforming growth factor, cf. e.g. Roberts and Sporn, Handbook of Experimental Pharmacology 95 (1990), page 419-472, editors: Sporn and Roberts), the DVR-group (Hötten et al., Biochem. Biophys. Res. Comm. 206 (1995), page 608-613 and further literature cited therein) including BMPs (bone morphogenetic protein, cf. e.g. Rosen and Thies, Growth Factors in Perinatal Development 30 (1993), page 39-58, editors: Tsang, Lemons and Balistreri) and GDFs (growth differentiation factors), the inhibin/activin (cf. e.g. Vale et al., The

Physiology of Reproduction, second edition (1994), page 1861-1878, editors: Knobil and Neill) and the GDNF protein family (Rosenthal, Neuron 22 (1999), page 201-203; Airaksinen et al. Mol Cell Neurosci 13 (1999), page 313-325). Although the members of the TGF- β superfamily show high 5 amino acid homologies in the mature part of the protein, in particular 7 conserved cysteines, they show considerable variations in their exact functions. Often individual growth factors of these families exhibit a plurality of functions at the same time, so that their application is of interest in various medical indications. Some of these multifunctional proteins also 10 have survival promoting effects on neurons in addition to functions such as e.g. regulation of the proliferation and differentiation in many cell types (Roberts and Sporn, supra; Sakurai et al., J. Biol. Chem. 269 (1994), page 14118-14122). Thus e.g. trophic effects on embryonic motoric and sensory 15 neurons were demonstrated for TGF- β in vitro (Martinou et al., Devl. Brain Res. 52, page 175-181 (1990) and Chalazonitis et al., Dev. Biol. 152, page 121-132 (1992)). In addition, effects promoting survival are shown for dopaminergic neurons of the mid-brain for the proteins TGF- β -1, -2, -3, 20 activin A and GDNF (glial cell line-derived neurotrophic factor), a protein which has structural similarities to TGF- β superfamily members, these effects being not mediated via astrocytes (Kriegstein et al., EMBO J. 14, page 736-742 (1995)).

Interesting members of the TGF- β superfamily or active variants thereof comprise the TGF- β proteins like TGF- β 1, TGF- β 2, TGF- β 3, TGF- β 4, TGF- β 5 25 (U.S. 5,284,763; EP 0376785; U.S. 4,886,747; DNA 7 (1988), page 1-8), EMBO J. 7 (1988), page 3737-3743), Mol. Endo. 2 (1988), page 1186-1195), J. Biol. Chem. 265 (1990), page 1089-1093), OP1, OP2 and OP3 30 proteins (U.S. 5,011,691, U.S. 5,652,337, WO 91/05802) as well as BMP2, BMP3, BMP4 (WO 88/00205, U.S. 5,013,649 and WO 89/10409, Science 242 (1988), page 1528-1534), BMP5, BMP6 and BMP-7 (OP1) 35 (Proc. Natl. Acad. Sci. 87 (1990), page 9841-9847, WO 90/11366), BMP8 (OP2) (WO 91/18098), BMP9 (WO 93/00432), BMP10 (WO 94/26893),

- 3 -

BMP11 (WO 94/26892), BMP12 (WO 95/16035), BMP13 (WO 95/16035),
BMP15 (WO 96/36710), BMP16 (WO 98/12322), BMP3b (Biochem.
Biophys. Res. Comm. 219 (1996), page 656-662), GDF1 (WO 92/00382
and Proc. Natl. Acad. Sci. 88 (1991), page 4250-4254), GDF8 (WO
5 94/21681), GDF10 (WO 95/10539), GDF11 (WO 96/01845), GDF5
(CDMP1, MP52) (WO 95/04819; WO 96/01316; WO 94/15949, WO
96/14335 and WO 93/16099 and Nature 368 (1994), page 639-643),
GDF6 (CDMP2, BMP13) (WO 95/01801, WO 96/14335 and WO 95/16035),
GDF7 (CDMP3, BMP12) (WO 95/01802 and WO 95/10635), GDF14 (WO
10 97/36926), GDF15 (WO 99/06445), GDF16 (WO 99/06556), 60A
(Proc. Natl. Acad. Sci. 88 (1991), page 9214-9218), DPP (Nature 325
(1987), page 81-84), Vgr-1 (Proc. Natl. Acad. Sci. 86 (1989), page 4554-
4558) Vg-1, (Cell 51 (1987), page 861-867), dorsalin (Cell 73 (1993), page
687-702), MIS (Cell 45 (1986), page 685-698), pCL13 (WO 97/00958),
15 BIP (WO 94/01557), inhibin α, activin βA and activin βB (EP 0222491),
activin βC (MP121) (WO 96/01316), activin βE and GDF12 (WO 96/02559
and WO 98/22492), activin βD (Biochem. Biophys. Res. Comm. 210
(1995), page 581-588), GDNF (Science 260 (1993), page 1130-1132, WO
93/06116), Neurturin (Nature 384 (1996), page 467-470), Persephin
20 (Neuron 20 (1998), page 245-253, WO 97/33911), Artemin (Neuron 21
(1998), page 1291-1302), Mic-1 (Proc. Natl. Acad. Sci USA 94 (1997),
page 11514-11519), Univin (Dev. Biol. 166 (1994), page 149-158), ADMP
(Development 121 (1995), page 4293-4301), Nodal (Nature 361 (1993),
page 543-547), Screw (Genes Dev. 8 (1994), page 2588-2601). Other
25 useful proteins include biologically active biosynthetic constructs including
biosynthetic proteins designed using sequences from two or more known
morphogenetic proteins. Examples of biosynthetic constructs are disclosed
in U.S. 5,011,691 (e.g. COP-1, COP-3, COP-4, COP-5, COP-7 and COP-
16). The disclosure of the cited publications including patents or patent
30 applications are incorporated herein by reference.

- 4 -

The occurrence of proteins of the TGF- β superfamily in various tissue stages and development stages corresponds with differences with regard to their exact functions as well as target sites, life span, requirements for auxiliary factors, necessary cellular physiological environment and/or resistance to degradation.

The proteins of the TGF- β superfamily exist as homodimers or heterodimers having a single disulfide bond. This disulfide bond is mediated by a specific and in most of the proteins conserved cysteine residue of the respective monomers. Up to now it was considered as indispensable for the biological activity that the protein is present in its dimeric form. Several publications indicated that biological activity can only be obtained for dimeric proteins and it was speculated that this dimer formation is important for further polymer formation of two or more dimers to achieve intercellular signal transmission by simultaneous binding to type I and type II receptors for the TGF- β superfamily proteins on cells. It was assumed that only this simultaneous binding to both kinds of receptors would allow for effective intercellular signal transmission for the benefit of the patient (Bone, volume 19 (1996), page 569-574).

20

A disadvantage of the use of these proteins as medicaments and their production is, that they are not readily obtainable in biologically active and sufficiently pure form by recombinant expression in prokaryotes without intensive renaturation procedures.

25

Thus it was the object of the present invention to provide a simple and inexpensive possibility to reproducibly produce proteins exhibiting high biological activity, wherein this biological activity should essentially correspond to that of the dimers of the proteins of said families.

30

This object is solved according to the invention by a protein selected from the members of the TGF- β protein superfamily, such protein being

- 5 -

necessarily monomeric due to substitution or deletion of a cysteine which is responsible for dimeric formation.

Surprisingly it has been found that the substitution or deletion of the 5 cysteine, which normally effects the dimerization in the proteins, results upon expression and correct folding (proper formation of the intramolecular disulfide bridges) in a monomeric protein that retains the biological activity of the dimeric form. Even more surprisingly, it was found that at least some of the monomeric proteins show a higher activity, based on the weight of 10 protein, than their respective dimeric forms. Apart from this improved biological activity an important advantage for the proteins according to the invention is that they can be expressed in a large amount in prokaryotic hosts and upon simple refolding of the monomers they are obtained in high purity and very high yield without the need to separate dimerized from non-dimerized (monomeric) protein. The findings of the present invention are 15 very surprising since, as already mentioned above, it was common understanding that only a dimer of the morphogenetic proteins has biological activity. Despite this understanding the proteins according to the invention ~~show an up to two-fold higher activity than that of the dimer on~~
20 the basis of protein weight. The smaller size of the proteins of the invention, while maintaining the biological activity, can also be considered as advantageous, e.g. for applications concerning the brain since the monomeric protein can much easier pass the blood-brain-barrier than the dimeric form.

25

The proteins according to the invention encompass all proteins of the mentioned protein families that are normally present in dimeric form. Also parts of such proteins that retain substantial activity or fusion proteins or precursor forms of proteins shall be considered as encompassed by the 30 present invention as well as biologically active naturally occurring or biosynthetic variants of TGF- β superfamily proteins, as long as they show at least considerable biological activity.

- 6 -

In a preferred embodiment of the present invention the monomeric protein is a mature protein or a biologically active part or variant thereof. The term "biologically active part or variant thereof" is meant to define either fragments retaining activity, precursor proteins that are e.g. cleaved at the 5 site of activity to the mature form or show biological activity themselves, or also variants that still maintain essentially the biological activity of the wild-type protein. Such variants preferably contain conservative amino acid substitutions, but especially at the N-terminal part of the mature proteins even considerable deletions or substitutions do not lead to a considerable 10 loss of biological activity. It is well within the skill of the man in the art to determine whether a certain protein shows the required biological activity. Proteins showing at least 70% and preferably at least 80% homology to the mature wild-type proteins of the above referenced protein families should be understood as encompassed by the present invention, as long as they 15 contain the deletion or substitution of a cysteine, as required for the proteins according the invention, and therefore do not form dimers.

It is especially preferred that proteins according to the invention contain at 20 least the 7 cysteine region characteristic for the TGF- β protein superfamily.

This specific 7 cysteine region is considered to be the most important part of the proteins in view of the biological activity. Therefore proteins retaining this critical region are preferred proteins according to the invention. It is disclosed in the state of the art which cysteine is responsible in a certain 25 protein family or protein for dimer formation (see for example: Schlunegger & Grutter (1992) Nature 358, 430-434; Daopin et al., (1992) Science 257, 369-373 and Griffith et al., Proc. Natl. Acad. Sci. 93 (1996), page 878-883). This cysteine has to be deleted or substituted by another amino acid to form a protein according to the invention.

The 7 cysteine region is known for many proteins of the TGF- β protein superfamily. In this region the respective location of the cysteine residues 30

to each other is important and is only allowed to vary slightly in order not to lose the biological activity. Consensus sequences for such proteins are known in the state of the art and all proteins complying with such consensus sequences are considered to be encompassed by the present invention.

In an especially preferred embodiment of the present invention the protein contains a consensus sequence according to the following sequence

10 C (Y)₂₈₋₂₉ C Y Y Y C (Y)₃₀₋₃₂ X C (Y)₃₃₋₃₄ C Y C (Formula I),

wherein C denotes cysteine, Y denotes any amino acid including cysteine and X denotes any amino acid except cysteine.

15 More preferably the protein according to the invention contains a consensus sequence according to the following sequence

 C (Y)₂₈ C Y Y Y C (Y)₃₀₋₃₂ X C (Y)₃₃ C Y C (Formula II),

wherein C, X and Y have the same meaning as defined above.

20 Even more preferably the protein according to the invention contains a consensus sequence according to the following sequence

 C (X)₂₈ C X X X C (X)₃₁₋₃₃ C (X)₃₄ C X C (Formula III),

wherein C and X have the same meaning as defined above.

25 In these consensus sequences especially preferred distances between the respective cysteine residues are contained, wherein also already the dimer forming cysteine is substituted by another amino acid. As with all proteins of said protein superfamily the location of and distance between the cysteines is more important than the identity of the other amino acids
30 contained in this region. Therefore, the consensus sequence shows the respective location of the cysteines, but does not show the identity of the

- 8 -

other amino acids, since these other amino acids are widely variable in the proteins of the TGF- β protein superfamily.

In a preferred embodiment of the present invention the monomeric protein
5 according to the invention is a morphogenetic protein.

Most of the members of the TGF- β protein superfamily are morphogenetic proteins that are useful for treatments where regulation of differentiation and proliferation of cells or progenitor cells is of interest. This can result in
10 replacement of damaged and/or diseased tissue like for example skeletal (bone, cartilage) tissue, connective tissue, periodontal or dental tissue, neural tissue, tissue of the sensory system, liver, pancreas, cardiac, blood vessel and renal tissue, uterine or thyroid tissue etc. Morphogenetic proteins are often useful for the treatment of ulcerative or inflammatory
15 tissue damage and wound healing of any kind such as enhanced healing of ulcers, burns, injuries or skin grafts. Especially preferred proteins according to the invention belong to the TGF- β , BMP, GDF, activin or GDNF families. Several BMP proteins which were originally discovered by their ability to induce bone formation, have been described, as also indicated above.
20 Meanwhile, several additional functions have been found as it is also true for members of the GDFs. These proteins show a very broad field of applications and especially are in addition to their bone and cartilage growth promoting activity (see for example: WO 88/00205, WO 90/11366, WO 91/05802) useful in periodontal disease, for inhibiting periodontal and tooth
25 tissue loss, for sealing tooth cavities, for enhancing integration of a tooth in a tooth socket (see for example: WO 96/26737, WO 94/06399, WO 95/24210), for connective tissue such as tendon or ligament (see for example: WO 95/16035), for improving survival of neural cells, for inducing growth of neural cells and repairing neural defects, for damaged CNS tissue
30 due to stroke or trauma (see for example: WO 97/34626, WO 94/03200, WO 95/05846), for maintaining or restoring sensory perception (see for example WO 98/20890, WO 98/20889), for renal failure (see for example:

WO 97/41880, WO 97/41881), for liver regeneration (see for example WO 94/06449), for regeneration of myocardium (see for example WO 98/27995), for treatment or preservation of tissues or cells for organ or tissue transplantation, for integrity of gastrointestinal lining (see for example 5 WO 94/06420), for increasing progenitor cell population as for example hematopoietic progenitor cells by ex vivo stimulation (see for example WO 92/15323), etc. One preferred member of the GDF family is the protein MP52 which is also termed GDF-5 or CDMP-1. Applications for MP52 reflect several of the already described applications for the BMP/GDF family.

10 MP52 is considered to be a very effective promoter of bone and cartilage formation as well as connective tissue formation (see for example WO 95/04819, Hötten et al., (1996), Growth Factors 13, 65-74, Storm et al., (1994) Nature 368, 639-643, Chang et al., (1994) J. Biol. Chem. 269 (45), 28227-28234). In this connection MP52 is useful for applications 15 concerning the joints between skeletal elements (see for example Storm & Kingsley (1996) Development 122, 3969-3979). One example for connective tissue is tendon and ligament (Wolfman et al., (1997), J. Clin. Invest. 100, 321-330, Aspenberg & Forslund (1999), Acta Orthop Scand 70, 51-54, WO 95/16035). MP52 is also useful for tooth (dental and

20 periodontal) applications (see for example WO 95/04819, WO 93/16099, Morotome et al. (1998), Biochem Biophys Res Comm 244, 85-90). MP52 is useful in wound repair of any kind. It is in addition very useful for promoting tissue growth in the neuronal system and survival of dopaminergic neurons, for example. MP52 in this connection is useful for 25 applications in neurodegenerative diseases like e.g. Parkinson's disease and possibly also Alzheimer's disease for Huntington chorea tissues (see for example WO 97/03188, Kriegstein et al., (1995) J. Neurosci Res. 42, 724-732, Sullivan et al., (1997) Neurosci Lett 233, 73-76, Sullivan et al. (1998), Eur. J. Neurosci 10, 3681-3688). MP52 allows to maintain nervous 30 function or to retain nervous function in already damaged tissues. MP52 is therefore considered to be a generally applicable neurotrophic factor. It is also useful for diseases of the eye, in particular retina cornea and optic

- nerve (see for example WO 97/03188, You et al. (1999), Invest Ophthalmol Vis Sci 40, 296-311). The monomeric MP52 is expected to show all the already described activities of the dimeric form as well as some further described activities as described for the dimeric BMP/GDF family members.
- 5 It is expected to be for example also useful for increasing progenitor cell populations and for stimulating differentiation of progenitor cells ex vivo. Progenitor cells can be cells which take part in the cartilage formation process or hematopoietic progenitor cells. It is also useful for damaged or diseased tissue where a stimulation of angiogenesis is advantageous (see
- 10 for example: Yamashita et al. (1997), Exp Cell Res 235, 218-226).

An especially preferred protein according to the invention therefore is protein MP52 or a biologically active part or variant thereof. Like in the already above mentioned definition of these terms MP52 can e.g. be used in its mature form, however, it can also be used as a fragment thereof at least containing the 7 cysteine region or also in a precursory form. Deviations at the N-terminal part of mature MP52 do not affect its activity to a considerable degree. Therefore, substitutions, deletions or additions on the N-terminal part of the proteins are still within the scope of the present invention. It might be useful to add a peptide to the N-terminal part of the protein, e.g. for purification reasons. It might not be necessary to cleave off this added peptide after expression and purification of the protein. Additional peptides at the N- or C-terminal part of the protein may also serve for the targeting of the protein to special tissues such as nerve or bone tissue or for the penetration of the blood/brain barrier. Generally, also fusion proteins of a monomeric protein according to the invention and another peptide or group are considered within the scope of the present invention, wherein these other peptides or groups are directing the localization of the fusion protein, e.g. because of an affinity to a certain tissue type etc. Examples for such fusion proteins are described in WO 97/23612. The protein containing such addition will retain its biological

- 11 -

activity at least as long as such addition does not impair the formation of the biologically active conformation of the protein.

In an especially preferred embodiment of the present invention the proteins 5 comprises the amino acid sequence according to SEQ.ID.NO.1 (DNA and protein sequence) and SEQ.ID.No.2 (protein sequence, only), respectively. SEQ.ID.NO.2 shows the complete protein sequence of the prepro protein of human MP52, as already disclosed in WO 95/04819. The start of the mature protein lies preferably in the area of amino acids 352-400, especially 10 preferred at amino acids 381 or 382. Therefore, the mature protein comprises amino acids 381-501 or 382-501. The first alanine of the mature protein can be deleted and the mature protein then preferably comprises amino acids 383-501. The cysteine at position 465 that is present in the 15 already described dimeric MP52 protein is according to the invention either deleted or substituted by another amino acid. This deletion or substitution is represented by Xaa at the respective position in SEQ.ID.Nos.1 and 2.

The activin/inhibin family proteins are of interest for applications related to contraception, fertility and pregnancy (see for example WO 94/19455, U.S.

20 5,102,868). They are also of interest for applications like repair or prevention of diseases of the nervous system, they can be used in the repair of organ tissue such as liver and even in bone and cartilage, too. In this connection MP121 (activin β C) is especially useful in applications for growth or regeneration of damaged and/or diseased tissue, especially the 25 liver tissue, neural tissue, skeletal tissue (see for example WO 96/01316, WO 98/22492 and WO 97/03188). MP121 is known to be predominantly expressed in the liver whereby the mRNA is markedly reduced after partial hepatectomy. MP121 is expected to regulate the liver mass (Zhang et al., Endocrine Journal 44 (1997), page 759-764). The monomeric MP121 30 shows all the already described activities of the dimeric form as well as some further described activities as described for the dimeric TGF- β superfamily members. It is for example also expected to be useful in

- 12 -

treatment of ulceration (for example stomach ulceration) and useful for integrity of gastrointestinal lining and for stimulating differentiation of progenitor cells ex vivo, treatment or preservation of mammalian tissue or cells, e.g. for organ or tissue transplantation.

5

A further preferred protein according to the invention therefore is MP121, a member of the activin/inhibin protein family. Also for this protein a biologically active part or variant thereof is encompassed by the present invention according to the above defined rules. An especially preferred 10 embodiment is shown in SEQ.ID.NO.3 (DNA and protein sequence) and SEQ.ID.NO.4 (protein sequence, only) respectively. SEQ.ID.NO.4 shows the complete amino acid sequence of the prepro protein of human MP121, that has already been disclosed in WO 96/01316. The start of the mature protein lies preferably between amino acids 217 and 247, most preferred 15 at amino acid 237. A preferred mature protein therefore comprises the mature part of the protein starting at amino acid 237 and ending at amino acid 352. However, also the precursor protein comprising the whole shown amino acid sequence is encompassed by the present invention. The cysteine at position 316 is according to the invention either deleted or substituted 20 by another amino acid, being represented by Xaa in SEQ.ID.Nos.3 and 4.

The amino acid by which the cysteine residue effecting the dimerization is substituted can be selected by any amino acid that does not impair the formation of a biologically active conformation. The amino acid is preferably 25 selected from the group of alanine, serine, threonine, leucine, isoleucine, glycine and valine.

The proteins according to the invention are in summary characterized by the absence of the cysteine residue in the amino acid sequence responsible for 30 the dimer formation. This absence can be effected by substitution of this cysteine by another amino acid or by deletion. In case of deletion, however, it must be assured for the protein that the formation of the biologically

- 13 -

active conformation is not hindered. The same is true for the selection of the substitution amino acid, wherein it is preferred to use an amino acid which has a form similar to cysteine.

- 5 The monomeric proteins according to the invention can be easily produced, in particular by expression in prokaryots and renaturation according to known methods. It is advantageous that the protein can be obtained in exceedingly biologically active form. The proteins exhibit in monomeric form about the same activity as the dimer so that based on the amount of active
10 substance only the same amount of the monomeric protein has to be used in order to obtain the same positive biological effects.

A further subject matter of the present invention is a nucleic acid encoding a protein according to the invention. It is obvious that the nucleic acid has
15 to have such a sequence that a deletion or substitution of the cysteine responsible for the dimer formation is achieved. The nucleic acid can be a naturally occurring nucleic acid, but also a recombinantly produced or processed nucleic acid. The nucleic acid can be both a DNA sequence and an RNA sequence, as long as the protein according to the invention can be
20 obtained from this nucleic acid upon expression in a suitable system.

In a preferred embodiment of the invention the nucleic acid is a DNA sequence. This DNA sequence in an especially preferred embodiment of the invention comprises a sequence as shown in SEQ.ID.NO.1 and
25 SEQ.ID.NO.3, respectively, or parts thereof. SEQ.ID.NO.1 shows a nucleic acid encoding MP52, wherein the codon for the cysteine responsible for the dimer formation is replaced by another codon which does not encode cysteine or deleted. This substitution or deletion is shown as "nnn" in the sequence protocols. SEQ.ID.NO.3 shows a nucleic acid encoding MP121,
30 wherein also the codon for the cysteine effecting the dimer formation is replaced by a respective different codon or deleted. Instead of the complete

- 14 -

sequences of SEQ.ID.NOs.1 or 3 also parts can be used that encode the mature proteins or fragments also described above.

It is preferred in the framework of the present invention that the nucleic acid apart from the coding sequences also contains expression control sequences. Such expression control sequences are known to the man skilled in the art and serve to control the expression of the encoded protein in a host cell. The host cell does not have to be an isolated cell, moreover, the nucleic acid can be expressed in the patient *in vivo* in the target tissue.

This can be done by inserting the nucleic acid into the cell genome, however, it is also possible to transform host cells with expression vectors containing a nucleic acid according to the invention. Such expression vectors are a further subject matter of the present invention, wherein the nucleic acid is inserted in a suitable vector system, the vector system being selected according to the desired expression of the protein. The vector system can be a eukaryotic vector system, but - in the framework of the present invention - it is preferably a prokaryotic vector system, with which the proteins can be produced in prokaryotic host cells in a particularly easy and pure manner. In addition, the expression vector can be a viral vector.

20

Also host cells in turn are a further subject matter of the present invention. The host cells are characterized in that they contain a nucleic acid according to the invention or an expression vector according to the invention and that they are able to use the information present in the nucleic acids and in the expression vector, respectively, for the expression of a monomeric protein according to the invention.

Although in the framework of the present invention also eukaryotic host cells are suitable for the production of the protein, it is, as mentioned already several times above, particularly advantageous that the protein according to the invention can be produced in prokaryotic host cells, which therefore represent a preferred embodiment of the present invention.

- 15 -

After such preferred expression in prokaryotic host cells the protein is purified and renatured according to known methods, thereby effecting intramolecular cystine bridge formation.

- 5 Since, however, not only in vitro production of the monomeric protein is possible, but also in vivo expression of a nucleic acid according to the invention, a further preferred embodiment is a eukaryotic host cell, and especially a eukaryotic host cell containing the DNA in its genome, or as an expression vector. Such host cell can also be useful for application to an
10 individual in need of morphogenic treatment.

Further subject matters of the present application are pharmaceutical compositions comprising at least one monomeric protein according to the invention or at least one nucleic acid encoding for such a protein or at least
15 one corresponding expression vector, or at least one eukaryotic host cell expressing the monomeric protein.

The protein itself, but also a nucleic acid according to the invention, an
expression vector or a host cell can be considered to be advantageous as
20 active substances in a pharmaceutical composition. Also combinations of monomeric proteins, with either biological activities in the same or different applications, can be used in preferred pharmaceutical compositions. Especially preferred for neuronal applications are combinations of MP52 with other TGF- β superfamily proteins, both in monomeric form, like for
25 example with GDNF (see WO 97/03188). Also preferred for neuronal applications are combinations of TGF- β with GDNF, both in monomeric form. Also for applications concerning cartilage and/or bone the combination of several monomeric proteins might be useful, like MP52 with a protein of TGF- β (see e.g. WO 92/09697) or MP52 with a cartilage
30 maintenance-inducing protein such as BMP-9 (see e.g. WO 96/39170). When a nucleic acid or an expression vector is used, however, it has to be ensured that when administering to the patient there has to be an

- 16 -

environment in which the nucleic acid and the expression vector, respectively, can be expressed and the protein according to the invention can be produced *in vivo* at the site of action. The same applies accordingly to the host cell according to the invention. When using expression vectors or host cells it is also possible that they encode more than one monomeric protein of the invention to produce a combination of two or more monomeric proteins.

It is advantageous to both the protein and the nucleic acid or the expression vector or the host cell when they are applied in and/or on a biocompatible matrix. The matrix material can be transplanted into the patient, e.g. surgically, wherein the protein either is effective on the surface of the matrix material or the protein or the DNA encoding the protein can be slowly released from the matrix material and then be effective over a long period of time. Additionally it is possible and advantageous to use a biodegradable matrix material in the pharmaceutical composition, wherein this material preferably dissolves during the protein induced tissue formation so that a protein or a nucleic acid contained therein is released and the newly formed tissue replaces the matrix material.

20

Finally, in case of applications relating to bone formation, it is advantageous to use a matrix material which is itself e.g. osteogenically active. By using such a matrix material it becomes possible to achieve a synergistic effect of protein and matrix material and to effect a particularly rapid and effective bone formation.

An especially preferred matrix material that can be used according to the invention is a matrix material as described in U.S. 5,231,169 and U.S. 5,776,193 and especially for applications like spinal fusion.

30

When using a combination of a matrix material and protein and/or nucleic acid and/or expression vector, it is preferable to sterilize such a combination

- 17 -

prior to its use. The matrix and the morphogenetic protein can be separately sterilized and then combined, but it is preferred to terminally sterilize the device consisting of matrix and morphogenetic protein. Terminal sterilization can be achieved by ionizing radiation as already described for dimeric 5 proteins (U.S. 5,674,292) but it is also advantageous to use ethylene oxide.

Of course this invention also comprises pharmaceutical compositions containing further substances like e.g. pharmacologically acceptable auxiliary and carrier substances. However, the protein according to the 10 invention, also in case a matrix material is used, does not necessarily have to be used together with this matrix material, but can also be administered systemically, wherein it concentrates preferably in the surrounding of an implanted matrix material.

-
- 15 For some applications the protein according to the invention and the nucleic acid forming this protein, respectively or the expression vector or host cell can preferably be present in an injectable composition. Implants are not necessary or possible for every form of application of the proteins according to the invention. However, it is also possible to provide an implantable 20 vessel or an implantable micropump containing for example semipermeable membranes in which the protein according to the invention or the nucleic acid generating it is contained, from which either one is slowly released over a prolonged period of time. The pharmaceutical composition according to the invention can also contain other vehicles which make it possible that 25 the proteins or the nucleic acids or the expression vectors encoding these proteins be transported to the site of activity and released there, wherein e.g. liposomes or nanospheres can be used. In principle, it is also possible to apply host cells, like e.g. implanted embryonic cells expressing the proteins. Cells transfected with recombinant DNA may be encapsulated prior 30 to implantation. Any other practicable but herein not explicitly described form of application of the pharmaceutical composition according the invention and their corresponding manufacture are also comprised by the

- 18 -

present invention, as long as they contain a protein according to the invention or a nucleic acid or an expression vector coding therefor, or a host cell expressing it.

- 5 Although the indications shall not be restricted herein and all indications exhibiting the dimeric form of the protein according to the invention are also comprised, in the following types of application for the compositions according to the invention are listed which are considered to be particularly preferred indications for the proteins of the present invention. On the one hand, there is the prevention or therapy of diseases associated with bone and/or cartilage damage or affecting bone and/or cartilage disease, or generally situations, in which cartilage and/or bone formation is desirable or for spinal fusion, and on the other hand, there is prevention or therapy of damaged or diseased tissue associated with connective tissue including tendon and/or ligament, periodontal or dental tissue including dental implants, neural tissue including CNS tissue and neuropathological situations, tissue of the sensory system, liver, pancreas, cardiac, blood vessel, renal, uterine and thyroid tissue, skin, mucous membranes, endothelium, epithelium, for promotion or induction of nerve growth, tissue regeneration, angiogenesis, wound healing including ulcers, burns, injuries or skin grafts, induction of proliferation of progenitor cells or bone marrow cells, for maintenance of a state of proliferation or differentiation for treatment or preservation of tissue or cells for organ or tissue transplantation, for integrity of gastrointestinal lining, for treatment of disturbances in fertility, contraception or pregnancy.

Diseases concerning sensory organs like the eye are also to be included in the preferred indication of the pharmaceutical composition according to the invention. As neuronal diseases again Parkinson's and Alzheimer's diseases can be mentioned as examples.

- 19 -

The pharmaceutical compositions according to the invention can be used in any desired way, the pharmaceutical compositions are formulated preferably for surgical local application, topical or systemic application. Auxiliary substances for the individual application form can of course be present in
5 the pharmaceutical composition according to the invention. For some applications it can be advantageous to add some further substances to the pharmaceutical composition as for example Vitamin D (WO 92/21365), parathyroid hormone related peptide (WO 97/35607), chordin (WO 98/21335), anti-fibrinolytic agent (EP 535091), anti-metabolites (WO
10 95/09004), alkyl cellulose (WO 93/00050), mannitol (WO 98/33514), sugar, glycine, glutamic acid hydrochloride (U.S. 5,385,887), antibiotics, antiseptics, amino acids and/or additives which improve the solubility or stability of the monomeric morphogenetic protein as for example nonionic detergents (e.g. Tween 80), basic amino acids, carrier proteins (e.g. serum albumin), full length propeptides of the TGF- β superfamily or parts thereof.
15

As can be already gathered from the description of proteins, nucleic acids and pharmaceutical compositions, the proteins according to the invention and respective nucleic acids, which provide for an expression of the
20 proteins at the site of activity, can advantageously be applied in all areas for which also the dimeric forms of the proteins, as described, can be applied. In the framework of the present invention therefore a further subject matter is the use of a pharmaceutical composition according to the present invention for the treatment or prevention of any indications of the dimeric
25 forms of the proteins according to the invention.

Herein it is again possible to conduct surgical operations and to implant the pharmaceutical composition (in particular contained on a matrix material), an administration in liquid or otherwise suitable form via, e.g. injection or
30 oral administration seems to be as suitable as a topical application for e.g. tissue regeneration.

- 20 -

Fig. 1A shows a two dimensional graph of the conformation of recombinantly produced dimeric MP52 with the deleted first alanine. In this figure the 7 cysteine bridges contained in a dimer are shown, wherein there are 3 intramolecular cystine bridges per monomer unit and 1 intermolecular cystine bridge connecting both monomers. Fig. 1B shows the monomeric protein according to the invention wherein the cysteine of the amino acid sequence of MP52 has been replaced by X that denotes any amino acid except cysteine.

10 **Examples**

The examples shall explain the invention more illustratively and are not considered to be restrictive.

15 **Expression of monomeric MP52 in *E. coli*, refolding , purification and possible test systems to determine the biological activity**

20 The mature part of human MP52 was mutated by converting Cysteine to Alanine at position 465 of SEQ ID NO 2. For this purpose the nucleotides at the position 2032 and 2033 of SEQ ID NO 1 were converted from TG to GC. The substitution of the nucleotides was performed by using the prokaryotic plasmid pBP2MP52m and a PCR method.

25 The vector pBP2MP52m is a derivative of the pBR322 plasmid containing an ampicillin resistance gene, a T7-promoter followed by a ribosomal binding site, a start codon, the mature part of MP52 (coding for the amino acids 382-501 in SEQ ID NO. 2 with a Cysteine at position 465), stop codons in each reading frame and a terminator. The plasmid was deposited at the DSM (DSM 10029, 2nd June 1995).

30 The mutation was performed by using the QuickChange™ Site-Directed Mutagenesis Kit with the PfuTurbo™ DNA polymerase and the Dpn I endonuclease from Stratagene (Catalog #200518) according to the

- 21 -

- instruction manual of the manufacturer. The oligonucleotide CCACACCACCCACCGCCTGTGTGCCACGC (SEQ ID NO. 5) and the oligonucleotide GCGTGGGCACACAGGCGGTGGGTGGTGTGG (SEQ ID NO. 6) were purified by polyacrylamide gel electrophoresis and used as the 5 mutagenic primers. The resulting plasmid pBP2MP52_{ALA} contained after the start codon the nucleotide sequence coding for the amino acids 382-501 in SEQ ID NO. 2 with an Alanine at position 465 which was verified by sequencing.
- 10 The expression of monomeric MP52 can be induced by providing a source of T7 RNA polymerase. Using the bacterial strain BL21(DE3)pLysS (Novagen) transformed with the plasmid pBP2MP52_{ALA} and inducing the T7 RNA polymerase gene according to the manufacturers instructions with IPTG, monomeric MP52 can be expressed in inclusion bodies which can be 15 isolated according to standard procedures. Further purification was done on a reversed phase column (Nucleosil 300-7C4, Machery-Nagel) with a 0 to 50% buffer B gradient (buffer A: 0.1% TFA in water, buffer B: 90% acetonitrile, 0.1 % TFA) in 50 minutes (flow rate: 2 ml/min). The fractions containing monomeric MP52 were pooled, lyophilized and stored at -70°C.
- 20 MP52 was solubilized in a denaturing buffer (6M Urea, 500 mM NaCl, 10 mM DTT, 1 mM EDTA , 20 mM Tris pH 8.3) and added for refolding in 9 times of a 50 mM Glycine-buffer system (pH 9.8) containing CHAPS (20 mM), NaCl (500 mM) and 3 mM GSSG and gently stirred at 4°C. After approximately 24 hours the sample was diluted 2.8 times with 14 mM 25 NaH₂PO₄ and subjected to isoelectric precipitation. After centrifugation the precipitate was dissolved in 0.1 % TFA and the folded monomer was further purified by reversed phase HPLC. For this purpose MP52 was loaded on a column (Aquapore Octyl 20 micron, Applied Biosystems) equilibrated with 25% buffer B (buffer A: 0.1% TFA in water, buffer B: 90% acetonitrile, 0.1 % TFA). Monomeric MP52 was eluted with a 25-60% 30 buffer B gradient in 70 minutes (flow rate 3 ml/min). Fractions containing purified refolded monomeric MP52 were pooled, lyophilized, stored at -70°C

and can be used in biological activity studies. Useful for biological activity studies of monomeric MP52 in the field of cartilage and bone induction are for example the measurement of increasing ALP activity (Takuwa et al., Am. J. Physiol. 257, E797-E803, 1989) using osteoprogenitor-like ROB-C26 cells (Yamaguchi et al., Calcif. Tissue Int. 49, 221-225, 1991) as described in WO95/04819 or ATDC5 cells (Riken Gene Bank, RCB 0565, embryonic cells which differentiate like cartilage cells). Useful activity tests showing the neurological capacities of refolded monomeric MP52 are the measurement of increased survival of dopaminergic neurons as described for example by Kriegstein et al. (J. Neuroscience Res. 42, 724-732, 1995) or Sullivan et al. (Neuroscience Letters 233, 73-76, 1997) or the outgrowth of nerve fibers from embryonic retina are described for example in the WO 97/03188. The angiogenic potential of folded monomeric MP52 can be verified for example in an *in vivo* corneal micropocket model. Briefly, Hydron can be used as a slow release pellet adapted from D'Amato et al (Proc. Natl. Acad. Sci. USA 91 (1994) 4082-4085). About 2 µg of monomeric MP52 can be dissolved in 20 µl of 50% acetonitrile, stabilized with 5 mg sucralfate (sucrose aluminum sulfate; Bukh Meditec, Copenhagen) and mixed with 20 µl of 12% (wt/vol) Hydron NCC (Interferon Science, New Brunswick, NJ) in ethanol. The mixture can be pipetted onto Teflon pegs and dried to produce a pellet. Subsequently the pellet can be implanted into corneal micropockets of the eye of a male New Zealand White rabbit. For this purpose an intrastromal tunnel, starting from a perpendicular linear incision in the pupillary plane and ending 2.75 mm prior to the limbus can be created. As a postsurgical care one single dose of erythromycin ointment should be given onto the surface of the cornea. About 10 days after implantation new capillaries which grow toward the implantation site should be seen. The outgrowth towards the pellet can reflect the chemotactic response of the endothelial cells to the released MP52 and can be quantified by measuring the vascularized area and the number of vessels at the limbus .

- 23 -

Monomeric MP52 isolated and purified from inclusion bodies but not subjected to the refolding process can be used as a negative control. Dimeric MP52 can be used as the positive control.

5 **Expression of monomeric MP121 in E.coli, refolding, purification and possible test systems to determine the biological activity**

The mature part of human MP121 was mutated by converting Cysteine to Alanine at position 316 of SEQ ID NO 4. For this purpose the nucleotides 10 at position 1073 and 1074 of SEQ ID NO. 3 were converted from TG to GC. The substitution of the nucleotides was performed essentially as described for MP52 in the above example with differences in the plasmid and the mutagenic primers. The pBP4MP121m plasmid was used which differs from the pBP2MP52m plasmid by containing the mature part of 15 MP121 (coding for the amino acids 237-352 in SEQ ID NO. 4 with a Cysteine at position 316) instead of the mature part of MP52 and by harboring a tetracycline resistance gene instead of the ampicillin resistance gene. As mutagenic primers the oligonucleotide CTGGAGGGGGCTCAGCCTGTGTACCCACGG (SEQ ID NO. 7) and the 20 oligonucleotide CCGTGGGTACACAGGCTGAGCCCCCTCCAG (SEQ ID NO. 8) were used.

The resulting plasmid pBP4MP121_{ALA} contained after the start codon the nucleotide sequence coding for the amino acids 237-352 in SEQ ID NO. 4 25 with an Alanine at position 316 which was verified by sequencing.

The expression of monomeric MP121, isolation of inclusion bodies and purification was performed essentially as described for MP52 in the above example, with the exception that another E.coli strain, the HMS 174 (DE3) 30 (Novagen), was used.

- 24 -

For biological activity studies of refolded monomeric MP121 showing the neurological capacities the same assays as mentioned for MP52 can be used. The influence of refolded monomeric MP121 on liver growth can be investigated for example on rat hepatocytes in primary cultures by inhibiting
5 EGF induced DNA synthesis. Briefly, hepatocytes can be isolated from rat (Wistar) liver and cultured according to Yasuda et al. (J. Clin. Invest. Vol. 92, 1491-1496 (1993)). The cells have to be washed prior to incubation with fresh serum-free medium containing 0.1 nM insulin, 0.1% BSA and 1 nM EGF. The solubilized refolded monomeric MP121 can be added to the
10 medium at various concentrations and subsequently the hepatocytes have to be incubated for 72h including 0.5 μ Ci [3 H]Thymidine/ml for the last 24 hours as described by Mead & Fausto (Proc. Natl. Acad. Sci. USA 86, 1558-15562 (1989)). [3 H]Thymidine incorporation into trichloracetic acid-precitable material can be measured as described by McNeil et al. (J. Cell
15 Biol. 101, 372-379 (1985)).

Stimulation of hematopoiesis can be determined for examples on bone marrow aspirate cultures as described in example 8 of WO98/22492.

SEQUENCE LISTING

5 <110> HyGene AG

<120> Monomeric Protein of the TGF-beta Family

10 <130> 20780pwomd

<140>

<141>

<150> EP99115613

15 <151> 1999-08-06

<160> 8

<170> PatentIn Ver. 2.1

20

<210> 1

<211> 2703

<212> DNA

<213> Homo sapiens

25

<220>

<221> CDS

<222> (640)..(2142)

30 <400> 1

ccatggcctc gaaagggcag cggtgatttt ttgcacataa atatatcgca cttaaatgag 60

tttagacaga atgacatcag agagtaatta aattggttt gggttggatt ccgtttccaa 120

35 ttcctgagtt caggttgtt aaagattttt ctgagcacct gcaggcctgt gagtgtgtgt 180

gtgtgtgtgt gtgtgtgtgt gtgtgtgtga agtattttca ctggaaagga ttcaaaaacta 240

40

gggggaaaaaa aaaactggag cacacaggca gcattacgcc attcttcctt ctggaaaaaa 300

- 26 -

tccctcagcc ttatacaagg ctcccttcaag ccctcagtca gttgtgcagg agaaaaggggg 360
 5
 cggttggctt tctccttca agaacgagtt attttcagct gctgactgga gacgggtgcac 420
 10 caagagtctc agactgagga gaaaggcttt ccttctgtcg ctactgtgc tgccgtgtgc 540
 15 tttgaaagtc cactccttc atgggttttc ctgccaaacc agaggcacct ttgtgtgtgc 600
 20 ctc ctc act ttc ttg ctt tgg tac ctg gct tgg ctg gac ctg gaa ttc 702
 Leu Leu Thr Phe Leu Leu Trp Tyr Leu Ala Trp Leu Asp Leu Glu Phe
 10 15 20
 atc tgc act gtg ttg ggt gcc cct gac ttg ggc cag aga ccc cag ggg 750
 25 Ile Cys Thr Val Leu Gly Ala Pro Asp Leu Gly Gln Arg Pro Gln Gly
 25 30 35
 acc agg cca gga ttg gcc aaa gca gag gcc aag gag agg ccc ccc ctg 798
 Thr Arg Pro Gly Leu Ala Lys Ala Glu Ala Lys Glu Arg Pro Pro Leu
 30 40 45 50
 gcc cgg aac gtc ttc agg cca ggg ggt cac agc tat ggt ggg ggg gcc 846
 Ala Arg Asn Val Phe Arg Pro Gly Gly His Ser Tyr Gly Gly Ala
 55 60 65
 35 acc aat gcc aat gcc agg gca aag gga ggc acc ggg cag aca gga ggc 894
 Thr Asn Ala Asn Ala Arg Ala Lys Gly Gly Thr Gly Gln Thr Gly Gly
 70 75 80 85
 40 ctg aca cag ccc aag aag gat gaa ccc aaa aag ctg ccc ccc aga ccg 942
 Leu Thr Gln Pro Lys Lys Asp Glu Pro Lys Lys Leu Pro Pro Arg Pro
 90 95 100

- 27 -

ggc ggc cct gaa ccc aag cca gga cac cct ccc caa aca agg cag gct 990
 Gly Gly Pro Glu Pro Lys Pro Gly His Pro Pro Gln Thr Arg Gln Ala
 105 110 115

5 aca gcc cgg act gtg acc cca aaa gga cag ctt ccc gga ggc aag gca 1038
 Thr Ala Arg Thr Val Thr Pro Lys Gly Gln Leu Pro Gly Gly Lys Ala
 120 125 130

10 ccc cca aaa gca gga tct gtc ccc agc tcc ttc ctg ctg aag aag gcc 1086
 Pro Pro Lys Ala Gly Ser Val Pro Ser Ser Phe Leu Leu Lys Lys Ala
 135 140 145

15 agg gag ccc ggg ccc cca cga gag ccc aag gag cgg ttt cgc cca ccc 1134
 Arg Glu Pro Gly Pro Pro Arg Glu Pro Lys Glu Pro Phe Arg Pro Pro
 150 155 160 165

20 ccc atc aca ccc cac gag tac atg ctc tcg ctg tac agg acg ctg tcc 1182
 Pro Ile Thr Pro His Glu Tyr Met Leu Ser Leu Tyr Arg Thr Leu Ser
 170 175 180

25 gat gct gac aga aag gga ggc aac agc agc gtg aag ttg gag gct ggc 1230
 Asp Ala Asp Arg Lys Gly Gly Asn Ser Ser Val Lys Leu Glu Ala Gly
 185 190 195

30 ctg gcc aac acc atc acc agc ttt att gac aaa ggg caa gat gac cga 1278
 Leu Ala Asn Thr Ile Thr Ser Phe Ile Asp Lys Gly Gln Asp Asp Arg
 200 205 210

35 ggt ccc gtg gtc agg aag cag agg tac gtg ttt gac att agt gcc ctg 1326
 Gly Pro Val Val Arg Lys Gln Arg Tyr Val Phe Asp Ile Ser Ala Leu
 215 220 225

40 gag aag gat ggg ctg ctg ggg gcc gag ctg cgg atc ttg cgg aag aag 1374
 Glu Lys Asp Gly Leu Leu Gly Ala Glu Leu Arg Ile Leu Arg Lys Lys
 230 235 240 245

45 ccc tcg gac acg gcc aag cca gcg gcc ccc gga ggc ggg cgg gct gcc 1422
 Pro Ser Asp Thr Ala Lys Pro Ala Ala Pro Gly Gly Arg Ala Ala
 250 255 260

50 cag ctg aag ctg tcc agc tgc ccc agc ggc cgg cag ccg gcc tcc ttg 1470
 Gln Leu Lys Leu Ser Ser Cys Pro Ser Gly Arg Gln Pro Ala Ser Leu
 265 270 275

- 28 -

ctg gat gtg cgc tcc gtg cca ggc ctg gac gga tct ggc tgg gag gtg 1518
 Leu Asp Val Arg Ser Val Pro Gly Leu Asp Gly Ser Gly Trp Glu Val
 280 285 290

5 ttc gac atc tgg aag ctc ttc cga aac ttt aag aac tcg gcc cag ctg 1566
 Phe Asp Ile Trp Lys Leu Phe Arg Asn Phe Lys Asn Ser Ala Gln Leu
 295 300 305

10 tgc ctg gag ctg gag gcc tgg gaa cgg ggc agg gcc gtc gac ctc cgt 1614
 Cys Leu Glu Leu Glu Ala Trp Glu Arg Gly Arg Ala Val Asp Leu Arg
 310 315 320 325

15 ggc ctg ggc ttc gac cgc gcc ccc cgg cag gtc cac gag aag gcc ctg 1662
 Gly Leu Gly Phe Asp Arg Ala Ala Arg Gln Val His Glu Lys Ala Leu
 330 335 340

20 ttc ctg gtg ttt ggc cgc acc aag aaa cgg gac ctg ttc ttt aat gag 1710
 Phe Leu Val Phe Gly Arg Thr Lys Lys Arg Asp Leu Phe Phe Asn Glu
 345 350 355

25 att aag gcc cgc tct ggc cag gac gat aag acc gtc tat gag tac ctg 1758
 Ile Lys Ala Arg Ser Gly Gln Asp Asp Lys Thr Val Tyr Glu Tyr Leu
 360 365 370

30 ttc agc cag cgg cga aaa cgg cgg gcc cca ctg gcc act cgc cag ggc 1806
 Phe Ser Gln Arg Arg Lys Arg Arg Ala Pro Leu Ala Thr Arg Gln Gly
 375 380 385

35 aag cga ccc agc aag aac ctt aag gct cgc tgc agt cgg aag gca ctg 1854
 Lys Arg Pro Ser Lys Asn Leu Lys Ala Arg Cys Ser Arg Lys Ala Leu
 390 395 400 405

40 cat gtc aac ttc aag gac atg ggc tgg gac gac tgg atc atc gca ccc 1902
 His Val Asn Phe Lys Asp Met Gly Trp Asp Asp Trp Ile Ile Ala Pro
 410 415 420

45 ctt gag tac gag gct ttc cac tgc gag ggg ctg tgc gag ttc cca ttg 1950
 Leu Glu Tyr Glu Ala Phe His Cys Glu Gly Leu Cys Glu Phe Pro Leu
 425 430 435

50 cgc tcc cac ctg gag ccc acg aat cat gca gtc atc cag acc ctg atg 1998
 Arg Ser His Leu Glu Pro Thr Asn His Ala Val Ile Gln Thr Leu Met
 440 445 450

- 29 -

aac tcc atg gac ccc gag tcc aca cca ccc acc nnn tgt gtg ccc acg 2046
 Asn Ser Met Asp Pro Glu Ser Thr Pro Pro Thr Xaa Cys Val Pro Thr
 455 460 465

5 cggtt ctgtt agt ccc atc agc atc ctc ttc att gac tct gcc aac aac gtg 2094
 Arg Leu Ser Pro Ile Ser Ile Leu Phe Ile Asp Ser Ala Asn Asn Val
 470 475 480 485

gtg tat aag cag tat gag gac atg gtc gtg gag tgg tgt ggc tgc agg 2142
 10 Val Tyr Lys Gln Tyr Glu Asp Met Val Val Glu Ser Cys Gly Cys Arg
 490 495 500

tagcagcaact ggccctctgt cttectgggt ggcacatccc aagagccccct tcctgcactc 2202

15 ctggaatcac agagggtca ggaagctgtg gcaggagcat ctacacagct tgggtgaaag 2262

gggattccaa taagcttgct cgctctctga gtgtgacttg ggctaaaggc cccctttat 2322

20 ccacaagttc ccctggctga ggattgctgc ccgtctgctg atgtgaccag tggcaggcac 2382

aggccagg agacagactc tgaatggac tgagtcccag gaaacagtgc tttccgatga 2442

gactcagccc accatttctc ctcacctggg ctttcctcagc ctctggactc tcctaagcac 2502

25 ctctcaggag agccacaggt gccactgcct cctcaaataca catttgtgcc tggtgacttc 2562

ctgtccctgg gacagtttag aagctgactg ggcaagagtg ggagagaaga ggagagggct 2622

tggatagagt tgaggagtgt gaggctgtta gactgttaga tttaaatgtta tattgttag 2682
 30 ataaaaagca aaactgtgcc t 2703

<210> 2

35 <211> 501

<212> PRT

<213> Homo sapiens

<400> 2

40 Met Arg Leu Pro Lys Leu Leu Thr Phe Leu Leu Trp Tyr Leu Ala Trp
 1 5 10 15

Leu Asp Leu Glu Phe Ile Cys Thr Val Leu Gly Ala Pro Asp Leu Gly
 20 25 30

- 30 -

	Gln Arg Pro Gln Gly Thr Arg Pro Gly Leu Ala Lys Ala Glu Ala Lys
	35 40 45
	Glu Arg Pro Pro Leu Ala Arg Asn Val Phe Arg Pro Gly Gly His Ser
5	50 55 60
	Tyr Gly Gly Gly Ala Thr Asn Ala Asn Ala Arg Ala Lys Gly Gly Thr
	65 70 75 80
10	Gly Gln Thr Gly Gly Leu Thr Gln Pro Lys Lys Asp Glu Pro Lys Lys
	85 90 95
	Leu Pro Pro Arg Pro Gly Gly Pro Glu Pro Lys Pro Gly His Pro Pro
	100 105 110
15	Gln Thr Arg Gln Ala Thr Ala Arg Thr Val Thr Pro Lys Gly Gln Leu
	115 120 125
20	Pro Gly Gly Lys Ala Pro Pro Lys Ala Gly Ser Val Pro Ser Ser Phe
	130 135 140
	Leu Leu Lys Lys Ala Arg Glu Pro Gly Pro Pro Arg Glu Pro Lys Glu
	145 150 155 160
25	Pro Phe Arg Pro Pro Pro Ile Thr Pro His Glu Tyr Met Leu Ser Leu
	165 170 175
	Tyr Arg Thr Leu Ser Asp Ala Asp Arg Lys Gly Gly Asn Ser Ser Val
	180 185 190
30	Lys Leu Glu Ala Gly Leu Ala Asn Thr Ile Thr Ser Phe Ile Asp Lys
	195 200 205
35	Gly Gln Asp Asp Arg Gly Pro Val Val Arg Lys Gln Arg Tyr Val Phe
	210 215 220
	Asp Ile Ser Ala Leu Glu Lys Asp Gly Leu Leu Gly Ala Glu Leu Arg
	225 230 235 240
40	Ile Leu Arg Lys Lys Pro Ser Asp Thr Ala Lys Pro Ala Ala Pro Gly
	245 250 255
	Gly Gly Arg Ala Ala Gln Leu Lys Leu Ser Ser Cys Pro Ser Gly Arg
	260 265 270

- 31 -

Gln Pro Ala Ser Leu Leu Asp Val Arg Ser Val Pro Gly Leu Asp Gly
275 280 285

Ser Gly Trp Glu Val Phe Asp Ile Trp Lys Leu Phe Arg Asn Phe Lys
5 290 295 300

Asn Ser Ala Gln Leu Cys Leu Glu Leu Glu Ala Trp Glu Arg Gly Arg
305 310 315 320

10 Ala Val Asp Leu Arg Gly Leu Gly Phe Asp Arg Ala Ala Arg Gln Val
325 330 335

His Glu Lys Ala Leu Phe Leu Val Phe Gly Arg Thr Lys Lys Arg Asp
340 345 350

15 Leu Phe Phe Asn Glu Ile Lys Ala Arg Ser Gly Gln Asp Asp Lys Thr
355 360 365

Val Tyr Glu Tyr Leu Phe Ser Gln Arg Arg Lys Arg Arg Ala Pro Leu
20 370 375 380

Ala Thr Arg Gln Gly Lys Arg Pro Ser Lys Asn Leu Lys Ala Arg Cys
385 390 395 400

25 Ser Arg Lys Ala Leu His Val Asn Phe Lys Asp Met Gly Trp Asp Asp
405 410 415

Trp Ile Ile Ala Pro Leu Glu Tyr Glu Ala Phe His Cys Glu Gly Leu
420 425 430

30 Cys Glu Phe Pro Leu Arg Ser His Leu Glu Pro Thr Asn His Ala Val
435 440 445

Ile Gln Thr Leu Met Asn Ser Met Asp Pro Glu Ser Thr Pro Pro Thr
35 450 455 460

Xaa Cys Val Pro Thr Arg Leu Ser Pro Ile Ser Ile Leu Phe Ile Asp
465 470 475 480

40 Ser Ala Asn Asn Val Val Tyr Lys Gln Tyr Glu Asp Met Val Val Glu
485 490 495

Ser Cys Gly Cys Arg
500

<210> 3
 <211> 2272
 <212> DNA
 5 <213> Homo sapiens

<220>
 <221> CDS
 <222> (128)..(1183)

10 <400> 3
 caaggagcca tgccagctgg acacacactt cttccagggc ctctggcagc caggacagag 60

ttgagaccac agctgtttag accctgagcc ctgagtcgtt attgctcaag aagggccttc 120

15 cccagca atg acc tcc tca ttg ctt ctg gcc ttt ctc ctc ctg gct cca 169
 Met Thr Ser Ser Leu Leu Leu Ala Phe Leu Leu Leu Ala Pro
 1 5 10

20 acc aca gtg gcc act ccc aga gct ggc ggt cag tgt cca gca tgt ggg 217
 Thr Thr Val Ala Thr Pro Arg Ala Gly Gly Gln Cys Pro Ala Cys Gly
 15 20 25 30

ggg ccc acc ttg gaa ctg gag agc cag cgg gag ctg ctt ctt gat ctg 265
 25 Gly Pro Thr Leu Glu Leu Glu Ser Gln Arg Glu Leu Leu Leu Asp Leu
 35 40 45

gcc aag aga agc atc ttg gac aag ctg cac ctc acc cag cgc cca aca 313
 Ala Lys Arg Ser Ile Leu Asp Lys Leu His Leu Thr Gln Arg Pro Thr
 30 50 55 60

ctg aac cgc cct gtg tcc aga gct gct ttg agg act gca ctg cag cac 361
 Leu Asn Arg Pro Val Ser Arg Ala Ala Leu Arg Thr Ala Leu Gln His
 65 70 75

35 ctc cac ggg gtc cca cag ggg gca ctt cta gag gac aac agg gaa cag 409
 Leu His Gly Val Pro Gln Gly Ala Leu Leu Glu Asp Asn Arg Glu Gln
 80 85 90

40 gaa tgt gaa atc atc agc ttt gct gag aca ggc ctc tcc acc atc aac 457
 Glu Cys Glu Ile Ile Ser Phe Ala Glu Thr Gly Leu Ser Thr Ile Asn
 95 100 105 110

- 33 -

cag act cgt ctt gat ttt cac ttc tcc tct gat aga act gct ggt gac 505
 Gln Thr Arg Leu Asp Phe His Phe Ser Ser Asp Arg Thr Ala Gly Asp
 115 120 125

5 agg gag gtc cag cag gcc agt ctc atg ttc ttt gtg cag ctc cct tcc 553
 Arg Glu Val Gln Gln Ala Ser Leu Met Phe Phe Val Gln Leu Pro Ser
 130 135 140

10 aat acc act tgg acc ttg aaa gtg aga gtc ctt gtg ctg ggt cca cat 601
 Asn Thr Thr Trp Thr Leu Lys Val Arg Val Leu Val Leu Gly Pro His
 145 150 155

15 aat acc aac ctc acc ttg gct act cag tac ctg ctg gag gtg gat gcc 649
 Asn Thr Asn Leu Thr Leu Ala Thr Gln Tyr Leu Leu Glu Val Asp Ala
 160 165 170

20 agt ggc tgg catcaa ctc ccc cta ggg cct gaa gct caa gct gcc tgc 697
 Ser Gly Trp His Gln Leu Pro Leu Gly Pro Glu Ala Gln Ala Ala Cys
 175 180 185 190

25 agc cag ggg cac ctg acc ctg gag ctg gta ctt gaa ggc cag gta gcc 745
 Ser Gln Gly His Leu Thr Leu Glu Leu Val Leu Glu Gly Gln Val Ala
 195 200 205

26 cag agc tca gtc atc ctg ggt gga gct gcc cat agg cct ttt gtg gca 793
 Gln Ser Ser Val Ile Leu Gly Gly Ala Ala His Arg Pro Phe Val Ala
 210 215 220

30 gcc cgg gtg aga gtt ggg ggc aaa cac cag att cac cga cga ggc atc 841
 Ala Arg Val Arg Val Gly Gly Lys His Gln Ile His Arg Arg Gly Ile
 225 230 235

35 gac tgc caa gga ggg tcc agg atg tgc tgt cga caa gag ttt ttt gtg 889
 Asp Cys Gln Gly Ser Arg Met Cys Cys Arg Gln Glu Phe Phe Val
 240 245 250

40 gac ttc cgt gag att ggc tgg cac gac tgg atc atc cag cct gag ggc 937
 Asp Phe Arg Glu Ile Gly Trp His Asp Trp Ile Ile Gln Pro Glu Gly
 255 260 265 270

tac gcc atg aac ttc tgc ata ggg cag tgc cca cta cac ata gca ggc 985
 Tyr Ala Met Asn Phe Cys Ile Gly Gln Cys Pro Leu His Ile Ala Gly
 275 280 285

- 34 -

atg cct ggt att gct gcc tcc ttt cac act gca gtg ctc aat ctt ctc 1033
 Met Pro Gly Ile Ala Ala Ser Ph His Thr Ala Val Leu Asn Leu Leu
 290 295 300

5 aag gcc aac aca gct gca ggc acc act gga ggg ggc tca nnn tgt gta 1081
 Lys Ala Asn Thr Ala Ala Gly Thr Thr Gly Gly Ser Xaa Cys Val
 305 310 315

10 ccc acg gcc cgg cgc ccc ctg tct ctg ctc tat tat gac agg gac agc 1129
 Pro Thr Ala Arg Arg Pro Leu Ser Leu Leu Tyr Tyr Asp Arg Asp Ser
 320 325 330

15 aac att gtc aag act gac ata cct gac atg gta gta gag gcc tgt ggg 1177
 Asn Ile Val Lys Thr Asp Ile Pro Asp Met Val Val Glu Ala Cys Gly
 335 340 345 350

tgc agt tagtctatgt gtggtatggg cagcccaagg ttgcatggga aaacacgcc 1233
 Cys Ser

20 ctacagaagt gcacttcctt gagaggaggg aatgacctca ttctctgtcc agaatgtgga 1293
 ctccctcttc ctgagcatct tatggaaatt accccacett tgacttgaag aaaccttcat 1353

25 ctaaagcaag tcacttgcc atttcctga ccactaccct ctttccttagg gcatagtcca 1413
 tcccccttagt ccatcccgt agccccactc cagggactca gaccatctc caaccatgag 1473

caatgccatc tggttcccag gcaaagacac ccttagctca ccttaatag accccataac 1533

30 ccactatgcc ttectgtctt ttctactcaa tggccccac tccaagatga gttgacacaa 1593
 ccccttcccc caattttgtt gnatctccag agaggccctt ctttggattc accaaagttt 1653

35 agatcaactgc tgccaaaat agaggcttac ctaccccccctt ctttggattg agccctgtc 1713
 cttcttagtt gtccaggtga actactaaag ctctcttgc ataccttcat ccatttttg 1773

tccctctctg ctttctcta tgcccttaag gggtgacttg cctgagctct atcacctgag 1833

40 ctccccctgcc ctctggcttc ctgctgaggt cagggcattt cttatccctg ttcctctct 1893
 gtcttaggtgt catggttctg tgtaactgtg gctattctgt gtccctacac tacctggcta 1953

45 ccccccttcca tggccccccagc tctgcctaca ttctgatttt tttttttttt ttttttttga 2013

- 35 -

aaagttaaaa attccttaat ttttatcc tggtaccact accacaattt acagggcaat 2073
atacctgatg taatgaaaag aaaaagaaaa agacaaagct acaacagata aaagacctca 2133
5 ggaatgtaca tctaattgac actacattgc attaatcaat agctgcactt tttgcaaact 2193
gtggctatga cagtcctgaa caagaagggt ttctgttta agctgcagta actttctga 2253
ctatggatca tcgttcctt 2272
10

<210> 4
<211> 352
<212> PRT
15 <213> Homo sapiens

<400> 4
Met Thr Ser Ser Leu Leu Ala Phe Leu Leu Leu Ala Pro Thr Thr
1 5 10 15
20 Val Ala Thr Pro Arg Ala Gly Gly Gln Cys Pro Ala Cys Gly Gly Pro
20 25 30

Thr Leu Glu Leu Glu Ser Gln Arg Glu Leu Leu Leu Asp Leu Ala Lys
25 35 40 45

Arg Ser Ile Leu Asp Lys Leu His Leu Thr Gln Arg Pro Thr Leu Asn
50 55 60

30 Arg Pro Val Ser Arg Ala Ala Leu Arg Thr Ala Leu Gln His Leu His
65 70 75 80

Gly Val Pro Gln Gly Ala Leu Leu Glu Asp Asn Arg Glu Gln Glu Cys
85 90 95

35 Glu Ile Ile Ser Phe Ala Glu Thr Gly Leu Ser Thr Ile Asn Gln Thr
100 105 110

Arg Leu Asp Phe His Phe Ser Ser Asp Arg Thr Ala Gly Asp Arg Glu
40 115 120 125

Val Gln Gln Ala Ser Leu Met Phe Phe Val Gln Leu Pro Ser Asn Thr
130 135 140

- 36 -

Thr Trp Thr Leu Lys Val Arg Val Leu Val Leu Gly Pro His Asn Thr
145 150 155 160

Asn Leu Thr Leu Ala Thr Gln Tyr Leu Leu Glu Val Asp Ala Ser Gly
5 165 170 175

Trp His Gln Leu Pro Leu Gly Pro Glu Ala Gln Ala Ala Cys Ser Gln
180 185 190

Gly His Leu Thr Leu Glu Leu Val Leu Glu Gly Gln Val Ala Gln Ser
10 195 200 205

Ser Val Ile Leu Gly Gly Ala Ala His Arg Pro Phe Val Ala Ala Arg
210 215 220

15 Val Arg Val Gly Gly Lys His Gln Ile His Arg Arg Gly Ile Asp Cys
225 230 235 240

Gln Gly Gly Ser Arg Met Cys Cys Arg Gln Glu Phe Phe Val Asp Phe
20 245 250 255

Arg Glu Ile Gly Trp His Asp Trp Ile Ile Gln Pro Glu Gly Tyr Ala
260 265 270

Met Asn Phe Cys Ile Gly Gln Cys Pro Leu His Ile Ala Gly Met Pro
25 275 280 285

Gly Ile Ala Ala Ser Phe His Thr Ala Val Leu Asn Leu Leu Lys Ala
290 295 300

Asn Thr Ala Ala Gly Thr Thr Gly Gly Ser Xaa Cys Val Pro Thr
30 305 310 315 320

Ala Arg Arg Pro Leu Ser Leu Leu Tyr Tyr Asp Arg Asp Ser Asn Ile
35 325 330 335

Val Lys Thr Asp Ile Pro Asp Met Val Val Glu Ala Cys Gly Cys Ser
340 345 350

40

<210> 5
<211> 30
<212> DNA
45 <213> Artificial Sequence

- 37 -

<220>

<223> Description of Artificial Sequence: mutagenic primer

5 <400> 5

ccacaccacc caccgcctgt gtgcccacgc

30

10 <210> 6

<211> 30

<212> DNA

<213> Artificial Sequence

15 <220>

<223> Description of Artificial Sequence: mutagenic primer

<400> 6

20 gcgtggggcac acaggcggtg ggtgggtgtgg

30

25 <210> 7

<211> 30

<212> DNA

<213> Artificial Sequence

30 <220>

<223> Description of Artificial Sequence: mutagenic primer

<400> 7

35 ctggaggggg ctcagcctgt gtacccacgg

30

40 <210> 8

<211> 30

<212> DNA

<213> Artificial Sequence

45 <220>

<223> Description of Artificial Sequence: mutagenic primer

- 38 -

<400> 8

ccgtgggtac acaggtctgag cccccctccag

30

Claims

1. Protein selected from the members of the TGF- β superfamily, characterized in that the protein is necessarily monomeric due to substitution or deletion of a cysteine which is responsible for dimer formation.
2. Protein according to claim 1, characterized in that the protein is a mature protein or a biologically active part or variant thereof.
3. Protein according to any one of the preceding claims, characterized in that the protein contains at least the 7 cysteine region characteristic for the TGF- β protein superfamily.
4. Protein according to claim 3, characterized in that it contains a consensus sequence according to
Formula I: C(Y)₂₅₋₂₉CYYYC(Y)₃₀₋₃₅XC(Y)₃₇₋₃₄CY or
Formula II: C(Y)₂₈CYYYC(Y)₃₀₋₃₂XC(Y)₃₁CY, wherein C denotes cysteine, Y denotes any amino acid and X denotes any amino acid except cysteine.
5. Protein according to any one of claims 1 to 4, characterized in that the protein is a morphogenetic protein.
6. Protein according to any one of the preceding claims, characterized in that the protein belongs to the TGF- β , BMP, GDF, activin or GDNF family.
7. Protein according to claim 6, characterized in that the protein is MP52 (GDF5) or a biologically active part or variant thereof.

- 40 -

8. Protein according to any one of the preceding claims,
characterized in that it comprises the amino acid sequence according
to SEQ.ID.NO.2 or a part thereof.
- 5 9. Protein according to claim 6,
characterized in that the protein is MP121 or a biologically active part
or variant thereof.
10. Protein according to claim 9,
characterized in that it comprises the amino acid sequence according
to SEQ.ID.NO.4 or a part thereof.
- 15 11. Protein according to any one of claims 1 to 10,
characterized in that the cysteine residue is substituted by an amino
acid selected from the group of alanine, serine, threonine, leucine,
isoleucine, glycine and valine.
- 20 12. Protein according to any one of claims 1 to 11,
characterized in that it contains additional amino acids that facilitate
or mediate the transfer and localization of the protein in a certain
tissue.
- 25 13. Nucleic acid,
characterized in that it encodes a protein according to any one of
claims 1 to 12.
14. Nucleic acid according to claim 13,
characterized in that it is a DNA.
- 30 15. Nucleic acid according to claim 13 or 14,
characterized in that it contains a sequence as shown in
SEQ.ID.NO.1 or a fragment thereof.

- 41 -

16. Nucleic acid according to claim 13 or 14,
characterized in that it contains a sequence as shown in
SEQ.ID.NO.3 or a fragment thereof.
- 5 17. Nucleic acid according to any one of claims 13 to 16,
characterized in that it further contains suitable expression control
sequences facilitating and/or driving expression of the encoded
protein.
- 10 18. Expression vector,
characterized in that it contains a nucleic acid according to any one
of claims 13 to 17 in a suitable vector system.
- 15 19. Expression vector according to claim 18,
characterized in that the vector system is suitable for prokaryotic
expression.
20. Host cell,
characterized in that it contains a nucleic acid according to any one
20 of claims 13 to 17 or an expression vector according to claims 18 or
19 and upon expression of said nucleic acid or vector is able to
produce a monomeric protein according to any one of claims 1 to 12.
- 25 21. Host cell according to claim 20,
characterized in that it is a prokaryotic host cell.
22. Host cell according to claim 20,
characterized in that it is an embryonal cell.
- 30 23. Pharmaceutical composition,
characterized in that it contains at least one protein according to any
one of claims 1 to 12 or at least one nucleic acid according to any

one of claims 13 to 17, at least one expression vector according to any one of claims 18 or 19 or at least one host cell according to claim 20 or 22.

- 5 24. Pharmaceutical composition according to claim 23,
characterized in that the protein and/or nucleic acid are contained in
and/or on a biocompatible matrix material.
- 10 25. Pharmaceutical composition according to claim 24,
characterized in that the matrix material is biodegradable.
- 15 26. Pharmaceutical composition according to claims 24 or 25,
characterized in that the matrix material is itself osteogenically active.
- 20 27. Pharmaceutical composition according to any one of claims 23 to 26,
for the prevention or therapy of diseases for which also the dimeric
form of the protein would be indicated.
- 25 28. Pharmaceutical composition according to claim 27,
for prevention or therapy of diseases associated with bone and/or
cartilage damage or affecting bone and/or cartilage disease or
situations in which cartilage and/or bone growth is desirable or for
spinal fusion.
- 30 29. Pharmaceutical composition according to claim 27,
for prevention or therapy of damaged or diseased tissue associated
with connective tissue including tendon and/or ligament, periodontal
or dental tissue including dental implants, neural tissue including CNS
tissue and neuropathological situations, tissue of the sensory system,
liver, pancreas, cardiac, blood vessel, renal, uterine and thyroid
tissue, skin, mucous membranes, endothelium, epithelium, for
promotion or induction of nerve growth, tissue regeneration,

- 43 -

angiogenesis, wound healing including ulcers, burns, injuries or skin grafts, induction of proliferation of progenitor cells or bone marrow cells, for maintenance of a state of proliferation or differentiation, for treatment or preservation of tissue or cells for organ or tissue transplantation, for integrity of gastrointestinal lining, for treatment of disturbances in fertility, contraception or pregnancy.

- 5
- 10
- 15
- 20
- 25
- 30
30. Pharmaceutical composition according to any one of claims 23 to 29 for surgical local application, topical or systemic application.
 31. Pharmaceutical composition according to any one of claims 23 to 30 characterized in that it further contains pharmacologically acceptable auxiliary substances.
 32. Pharmaceutical composition according to any one of claims 30 or 31, characterized in that the composition is injectable.
 33. Pharmaceutical composition according to anyone of claims 30 to 32, characterized in that it is contained in a vehicle that allows to direct and release the composition to a determined site of action.
 34. Pharmaceutical composition according to claim 33, characterized in that the vehicle is selected from liposomes, nanospheres, larger implantable containers and micropumps.
 35. Use of a pharmaceutical composition according to any one of claims 23 to 34 for the prevention or treatment of any indications of the dimeric form of the protein.

Fig. 1 A

Name: MP52, dimeric form

Formula	$C_{1184}H_{1844}N_{330}O_{350}S_{22}$
Molecular weight	26994 Dalton
Amino acid composition	238 amino acids
Disulfide bond	7 bonds

Primary structure





Fig. 1 B



SEQUENCE LISTING

<110> HyGene AG

<120> Monomeric Protein of the TGF-beta Family

<130> 20780pwomd

<140>

<141>

<150> EP99115613

<151> 1999-08-06

<160> 8

<170> PatentIn Ver. 2.1

<210> 1

<211> 2703

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (640)..(2142)

<400> 1

ccatggcctc gaaagggcag cggtgatttt tttcacataa atatatcgca cttaaatgag 60

ttagacagc atgacatcg agagtaatta aattggtttgcgttggaaatt ccgtttccaa 120

ttcctgagtt caggttgtta aaagattttt ctgagcacct gcaggcctgt gagtgtgtgt 180

gtgtgtgtgt gtgtgtgtgt gtgtgtgtga agtattttca ctggaaagga ttcaaaaacta 240

gggggaaaaaa aaaactggag cacacaggca gcattacgcc attcttcctt cttggaaaaaa 300

tccctcagcc ttataacaagc ctccttcaag ccctcagtca gttgtgcagg agaaaggggg 360

cgttggctt ttcctttca agaacgagtt atttcagct gctgactgga gacggtgac 420

gtctggatac gagagcattt ccactatggg actggataca aacacacacc cggcagactt 480

caagagtctc agactgagga gaaagccttt ccttctgctg ctactgctgc tgccgctgct 540

tttggaaagtc cactccttca atgggttttc ctgccaaacc agaggcacct ttgctgctgc 600

cgctgttctc tttggtgtca ttcagcggct ggccagagg atg aga ctc ccc aaa 654
 Met Arg Leu Pro Lys
 1 5

ctc ctc act ttc ttg ctt tgg tac ctg gct tgg ctg gac ctg gaa ttc 702
 Leu Leu Thr Phe Leu Leu Trp Tyr Leu Ala Trp Leu Asp Leu Glu Phe
 10 15 20

atc tgc act gtg ttg ggt gcc cct gac ttg ggc cag aga ccc cag ggg 750
 Ile Cys Thr Val Leu Gly Ala Pro Asp Leu Gly Gln Arg Pro Gln Gly
 25 30 35

acc agg cca gga ttg gcc aaa gca gag gcc aag gag agg ccc ccc ctg 798
 Thr Arg Pro Gly Leu Ala Lys Ala Glu Ala Lys Glu Arg Pro Pro Leu
 40 45 50

gcc cggttccatggccatggccatggccatggccatggccatggccatggccatggcc 846
 Ala Arg Asn Val Phe Arg Pro Gly Gly His Ser Tyr Gly Gly Gly Ala
 55 60 65

acc aat gcc aat gcc agg gca aag gga ggc acc ggg cag aca gga ggc 894
 Thr Asn Ala Asn Ala Arg Ala Lys Gly Gly Thr Gly Gln Thr Gly Gly
 70 75 80 85

ctg aca cag ccc aag aag gat gaa ccc aaa aag ctg ccc ccc aga ccg 942
 Leu Thr Gln Pro Lys Lys Asp Glu Pro Lys Lys Leu Pro Pro Arg Pro
 90 95 100

ggc ggc cct gaa ccc aag cca gga cac cct ccc caa aca agg cag gct 990
 Gly Gly Pro Glu Pro Lys Pro Gly His Pro Pro Gln Thr Arg Gln Ala
 105 110 115

aca gcc cggttccatggccatggccatggccatggccatggccatggccatggccatggcc 1038
 Thr Ala Arg Thr Val Thr Pro Lys Gly Gln Leu Pro Gly Gly Lys Ala
 120 125 130

ccc cca aaa gca gga tct gtc ccc agc tcc ttc ctg ctg aag aag gcc 1086
 Pro Pro Lys Ala Gly Ser Val Pro Ser Ser Phe Leu Leu Lys Lys Ala
 135 140 145

agg gag ccc ggg ccc cca cga gag ccc aag gag ccg ttt cgc cca ccc 1134
 Arg Glu Pro Gly Pro Pro Arg Glu Pro Lys Glu Pro Phe Arg Pro Pro
 150 155 160 165

ccc atc aca ccc cac gag tac atg ctc tcg ctg tac agg acg ctg tcc 1182
 Pro Ile Thr Pro His Glu Tyr Met Leu Ser Leu Tyr Arg Thr Leu Ser
 170 175 180

gat gct gac aga aag gga ggc aac agc agc gtg aag ttg gag gct ggc 1230
 Asp Ala Asp Arg Lys Gly Gly Asn Ser Ser Val Lys Leu Glu Ala Gly
 185 190 195

ctg gcc aac acc atc acc agc ttt att gac aaa ggg caa gat gac cga 1278
 Leu Ala Asn Thr Ile Thr Ser Phe Ile Asp Lys Gly Gln Asp Asp Arg
 200 205 210

ggt ccc gtg gtc agg aag cag agg tac gtg ttt gac att agt gcc ctg 1326
 Gly Pro Val Val Arg Lys Gln Arg Tyr Val Phe Asp Ile Ser Ala Leu
 215 220 225

gag aag gat ggg ctg ctg ggg gcc gag ctg cgg atc ttg cgg aag aag 1374
 Glu Lys Asp Gly Leu Leu Gly Ala Glu Leu Arg Ile Leu Arg Lys Lys
 230 235 240 245

ccc tcg gac acg gcc aag cca gcg gcc ccc gga ggc ggg cgg gct gcc 1422
 Pro Ser Asp Thr Ala Lys Pro Ala Ala Pro Gly Gly Arg Ala Ala
 250 255 260

cag ctg aag ctg tcc agc tgc ccc agc ggc cgg cag ccg gcc tcc ttg 1470
 Gln Leu Lys Leu Ser Ser Cys Pro Ser Gly Arg Gln Pro Ala Ser Leu
 265 270 275

ctg gat gtg cgc tcc gtg cca ggc ctg gac gga tct ggc tgg gag gtg 1518
 Leu Asp Val Arg Ser Val Pro Gly Leu Asp Gly Ser Gly Trp Glu Val
 280 285 290

ttc gac atc tgg aag ctc ttc cga aac ttt aag aac tcg gcc cag ctg 1566
 Phe Asp Ile Trp Lys Leu Phe Arg Asn Phe Lys Asn Ser Ala Gln Leu
 295 300 305

tgc ctg gag ctg gag gcc tgg gaa cgg ggc agg gcc gtg gac ctc cgt 1614
 Cys Leu Glu Leu Glu Ala Trp Glu Arg Gly Arg Ala Val Asp Leu Arg
 310 315 320 325

ggc ctg ggc ttc gac cgc gcc gcc cgg cag gtc cac gag aag gcc ctg 1662
 Gly Leu Gly Phe Asp Arg Ala Ala Arg Gln Val His Glu Lys Ala Leu
 330 335 340

ttc ctg gtg ttt ggc cgc acc aag aaa cgg gac ctg ttc ttt aat gag 1710
 Phe Leu Val Phe Gly Arg Thr Lys Lys Arg Asp Leu Phe Phe Asn Glu
 345 350 355

att aag gcc cgc tct ggc cag gac gat aag acc gtg tat gag tac ctg 1758
 Ile Lys Ala Arg Ser Gly Gln Asp Asp Lys Thr Val Tyr Glu Tyr Leu
 360 365 370

ttc agc cag cgg cga aaa cgg cgg gcc cca ctg gcc act cgc cag ggc	1806		
Phe Ser Gln Arg Arg Lys Arg Arg Ala Pro Leu Ala Thr Arg Gln Gly			
375	380	385	
aag cga ccc agc aag aac ctt aag gct cgc tgc agt cgg aag gca ctg	1854		
Lys Arg Pro Ser Lys Asn Leu Lys Ala Arg Cys Ser Arg Lys Ala Leu			
390	395	400	405
cat gtc aac ttc aag gac atg ggc tgg gac gac tgg atc atc gca ccc	1902		
His Val Asn Phe Lys Asp Met Gly Trp Asp Asp Trp Ile Ile Ala Pro			
410	415	420	
ctt gag tac gag gct ttc cac tgc gag ggg ctg tgc gag ttc cca ttg	1950		
Leu Glu Tyr Glu Ala Phe His Cys Glu Gly Leu Cys Glu Phe Pro Leu			
425	430	435	
cgc tcc cac ctg gag ccc acg aat cat gca gtc atc cag acc ctg atg	1998		
Arg Ser His Leu Glu Pro Thr Asn His Ala Val Ile Gln Thr Leu Met			
440	445	450	
aac tcc atg gac ccc gag tcc aca cca ccc acc nnn tgt gtg ccc acg	2046		
Asn Ser Met Asp Pro Glu Ser Thr Pro Pro Thr Xaa Cys Val Pro Thr			
455	460	465	
cgg ctg agt ccc atc agc atc ctc ttc att gac tct gcc aac aac gtg	2094		
Arg Leu Ser Pro Ile Ser Ile Leu Phe Ile Asp Ser Ala Asn Asn Val			
470	475	480	485
gtg tat aag cag tat gag gac atg gtc gtg gag tcg tgt ggc tgc agg	2142		
Val Tyr Lys Gln Tyr Glu Asp Met Val Val Glu Ser Cys Gly Cys Arg			
490	495	500	
tagcagcaact ggccctctgt cttcctgggt ggcacatccc aagagcccc tcctgcactc	2202		
ctggaatcac agaggggtca ggaagctgtg gcaggagcat ctacacagct tgggtgaaag	2262		
gggattccaa taagcttgct cgctctctga gtgtgacttg ggctaaaggc ccccttttat	2322		
ccacaagttc ccctggctga ggattgctgc ccgtctgctg atgtgaccag tggcaggcac	2382		
agg tccaggg agacagactc tgaatggac tgagtcccag gaaacagtgc tttccgatga	2442		
gactcagccc accatttctc ctacacctggg ccttctcagc ctctggactc tcctaaggcac	2502		
ctctcaggag agccacaggt gccactgcct cctcaaataca catttgcc tggtgacttc	2562		
ctgtccctgg gacagttgag aagctgactg ggcaagagtg ggagagaaga ggagagggct	2622		

tggatagagt tgaggagtgt gaggctgtta gactgttaga tttaaatgta tattgatgag 2682

ataaaaagca aaactgtgcc t 2703

<210> 2

<211> 501

<212> PRT

<213> Homo sapiens

<400> 2

Met Arg Leu Pro Lys Leu Leu Thr Phe Leu Leu Trp Tyr Leu Ala Trp
1 5 10 15

Leu Asp Leu Glu Phe Ile Cys Thr Val Leu Gly Ala Pro Asp Leu Gly
20 25 30

Gln Arg Pro Gln Gly Thr Arg Pro Gly Leu Ala Lys Ala Glu Ala Lys
35 40 45

Glu Arg Pro Pro Leu Ala Arg Asn Val Phe Arg Pro Gly Gly His Ser
50 55 60

Tyr Gly Gly Gly Ala Thr Asn Ala Asn Ala Arg Ala Lys Gly Gly Thr
65 70 75 80

Gly Gln Thr Gly Gly Leu Thr Gln Pro Lys Lys Asp Glu Pro Lys Lys
85 90 95

Leu Pro Pro Arg Pro Gly Gly Pro Glu Pro Lys Pro Gly His Pro Pro
100 105 110

Gln Thr Arg Gln Ala Thr Ala Arg Thr Val Thr Pro Lys Gly Gln Leu
115 120 125

Pro Gly Gly Lys Ala Pro Pro Lys Ala Gly Ser Val Pro Ser Ser Phe
130 135 140

Leu Leu Lys Lys Ala Arg Glu Pro Gly Pro Pro Arg Glu Pro Lys Glu
145 150 155 160

Pro Phe Arg Pro Pro Pro Ile Thr Pro His Glu Tyr Met Leu Ser Leu
165 170 175

Tyr Arg Thr Leu Ser Asp Ala Asp Arg Lys Gly Gly Asn Ser Ser Val
180 185 190

Lys Leu Glu Ala Gly Leu Ala Asn Thr Ile Thr Ser Phe Ile Asp Lys

195	200	205
-----	-----	-----

Gly Gln Asp Asp Arg Gly Pro Val Val Arg Lys Gln Arg Tyr Val Phe	210	215
		220

Asp Ile Ser Ala Leu Glu Lys Asp Gly Leu Leu Gly Ala Glu Leu Arg	225	230
		235
		240

Ile Leu Arg Lys Lys Pro Ser Asp Thr Ala Lys Pro Ala Ala Pro Gly	245	250
		255

Gly Gly Arg Ala Ala Gln Leu Lys Leu Ser Ser Cys Pro Ser Gly Arg	260	265
		270

Gln Pro Ala Ser Leu Leu Asp Val Arg Ser Val Pro Gly Leu Asp Gly	275	280
		285

Ser Gly Trp Glu Val Phe Asp Ile Trp Lys Leu Phe Arg Asn Phe Lys	290	295
		300

Asn Ser Ala Gln Leu Cys Leu Glu Leu Glu Ala Trp Glu Arg Gly Arg	305	310
		315
		320

Ala Val Asp Leu Arg Gly Leu Gly Phe Asp Arg Ala Ala Arg Gln Val	325	330
		335

His Glu Lys Ala Leu Phe Leu Val Phe Gly Arg Thr Lys Lys Arg Asp	340	345
		350

Leu Phe Phe Asn Glu Ile Lys Ala Arg Ser Gly Gln Asp Asp Lys Thr	355	360
		365

Val Tyr Glu Tyr Leu Phe Ser Gln Arg Arg Lys Arg Arg Ala Pro Leu	370	375
		380

Ala Thr Arg Gln Gly Lys Arg Pro Ser Lys Asn Leu Lys Ala Arg Cys	385	390
		395
		400

Ser Arg Lys Ala Leu His Val Asn Phe Lys Asp Met Gly Trp Asp Asp	405	410
		415

Trp Ile Ile Ala Pro Leu Glu Tyr Glu Ala Phe His Cys Glu Gly Leu	420	425
		430

Cys Glu Phe Pro Leu Arg Ser His Leu Glu Pro Thr Asn His Ala Val	435	440
		445

Ile Gln Thr Leu Met Asn Ser Met Asp Pro Glu Ser Thr Pro Pro Thr

450	455	460
-----	-----	-----

Xaa Cys Val Pro Thr Arg Leu Ser Pro Ile Ser Ile Leu Phe Ile Asp		
465	470	475
		480

Ser Ala Asn Asn Val Val Tyr Lys Gln Tyr Glu Asp Met Val Val Glu		
485	490	495

Ser Cys Gly Cys Arg	
500	

<210> 3

<211> 2272

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (128)..(1183)

<400> 3

caaggagcca tgccagctgg acacacactt cttccagggc ctctggcagc caggacagag 60

ttgagaccac agctgttgag accctgagcc ctgagtctgt attgctcaag aaggcccttc 120

cccagca atg acc tcc tca ttg ctt ctg gcc ttt ctc ctc ctg gct cca 169
Met Thr Ser Ser Leu Leu Leu Ala Phe Leu Leu Leu Ala Pro

1	5	10
---	---	----

acc aca gtg gcc act ccc aga gct ggc ggt cag tgt cca gca tgt ggg 217
Thr Thr Val Ala Thr Pro Arg Ala Gly Gly Gln Cys Pro Ala Cys Gly

15	20	25	30
----	----	----	----

ggg ccc acc ttg gaa ctg gag agc cag cgg gag ctg ctt ctt gat ctg 265
Gly Pro Thr Leu Glu Leu Ser Gln Arg Glu Leu Leu Leu Asp Leu
35 40 45

gcc aag aga agc atc ttg gac aag ctg cac ctc acc cag cgc cca aca 313
Ala Lys Arg Ser Ile Leu Asp Lys Leu His Leu Thr Gln Arg Pro Thr
50 55 60

ctg aac cgc cct gtg tcc aga gct gct ttg agg act gca ctg cag cac 361
Leu Asn Arg Pro Val Ser Arg Ala Ala Leu Arg Thr Ala Leu Gln His
65 70 75

ctc cac ggg gtc cca cag ggg gca ctt cta gag gac aac agg gaa cag 409

Leu His Gly Val Pro Gln Gly Ala Leu Leu Glu Asp Asn Arg Glu Gln			
80	85	90	
gaa tgt gaa atc atc agc ttt gct gag aca ggc ctc tcc acc atc aac	457		
Glu Cys Glu Ile Ile Ser Phe Ala Glu Thr Gly Leu Ser Thr Ile Asn			
95	100	105	110
cag act cgt ctt gat ttt cac ttc tcc tct gat aga act gct ggt gac	505		
Gln Thr Arg Leu Asp Phe His Phe Ser Ser Asp Arg Thr Ala Gly Asp			
115	120	125	
agg gag gtc cag cag gcc agt ctc atg ttc ttt gtg cag ctc cct tcc	553		
Arg Glu Val Gln Gln Ala Ser Leu Met Phe Phe Val Gln Leu Pro Ser			
130	135	140	
aat acc act tgg acc ttg aaa gtg aga gtc ctt gtg ctg ggt cca cat	601		
Asn Thr Thr Trp Thr Leu Lys Val Arg Val Leu Val Leu Gly Pro His			
145	150	155	
aat acc aac ctc acc ttg gct act cag tac ctg ctg gag gtg gat gcc	649		
Asn Thr Asn Leu Thr Leu Ala Thr Gln Tyr Leu Leu Glu Val Asp Ala			
160	165	170	
agt ggc tgg cat caa ctc ccc cta ggg cct gaa gct caa gct gcc tgc	697		
Ser Gly Trp His Gln Leu Pro Leu Gly Pro Glu Ala Gln Ala Ala Cys			
175	180	185	190
agc cag ggg cac ctg acc ctg gag ctg gta ctt gaa ggc cag gta gcc	745		
Ser Gln Gly His Leu Thr Leu Glu Leu Val Leu Glu Gly Gln Val Ala			
195	200	205	
cag agc tca gtc atc ctg ggt gga gct gcc cat agg cct ttt gtg gca	793		
Gln Ser Ser Val Ile Leu Gly Gly Ala Ala His Arg Pro Phe Val Ala			
210	215	220	
gcc cgg gtg aga gtt ggg ggc aaa cac cag att cac cga cga ggc atc	841		
Ala Arg Val Arg Val Gly Gly Lys His Gln Ile His Arg Arg Gly Ile			
225	230	235	
gac tgc caa gga ggg tcc agg atg tgc tgt cga caa gag ttt ttt gtg	889		
Asp Cys Gln Gly Gly Ser Arg Met Cys Cys Arg Gln Glu Phe Phe Val			
240	245	250	
gac ttc cgt gag att ggc tgg cac gac tgg atc atc cag cct gag ggc	937		
Asp Phe Arg Glu Ile Gly Trp His Asp Trp Ile Ile Gln Pro Glu Gly			
255	260	265	270
tac gcc atg aac ttc tgc ata ggg cag tgc cca cta cac ata gca ggc	985		

Tyr Ala Met Asn Phe Cys Ile Gly Gln Cys Pro Leu His Ile Ala Gly
 275 280 285

atg cct ggt att gct gcc tcc ttt cac act gca gtg ctc aat ctt ctc 1033
 Met Pro Gly Ile Ala Ala Ser Phe His Thr Ala Val Leu Asn Leu Leu
 290 295 300

aag gcc aac aca gct gca ggc acc act gga ggg ggc tca nnn tgt gta 1081
 Lys Ala Asn Thr Ala Ala Gly Thr Thr Gly Gly Ser Xaa Cys Val
 305 310 315

ccc acg gcc cgg cgc ccc ctg tct ctg ctc tat tat gac agg gac agc 1129
 Pro Thr Ala Arg Arg Pro Leu Ser Leu Leu Tyr Tyr Asp Arg Asp Ser
 320 325 330

aac att gtc aag act gac ata cct gac atg gta gta gag gcc tgt ggg 1177
 Asn Ile Val Lys Thr Asp Ile Pro Asp Met Val Val Glu Ala Cys Gly
 335 340 345 350

tgc agt tagtctatgt gtggtatggg cagcccaagg ttgcattggaa aaacacgccc 1233
 Cys Ser

ctacagaagt gcacttcctt gagaggaggg aatgaccta ttctctgtcc agaatgtgga 1293

ctccctcttc ctgagcatct tatggaaatt accccacett tgacttgaag aaaccttcat 1353

ctaaagcaag tcactgtgcc atcttctga ccactaccct ctttccttagg gcatagtcca 1413

tcccgctagt ccatcccgt agccccactc cagggactca gacccatctc caaccatgag 1473

caatgccatc tggttcccaag gcaaagacac ccttagctca cctttaatag accccataac 1533

ccactatgcc ttctctgcct ttctactcaa tggccccac tccaagatga gttgacacaa 1593

ccccttcccc caattttgtt ggatctccag agaggccctt ctttggattc accaaagttt 1653

agatcaactgc tgccaaaat agaggcttac ctaccccccctt ctttggatgtc agccctgtc 1713

cttcttagtt gtccaggta actactaaag ctctcttgc ataccttcat ccatttttg 1773

tccttctctg cttttctcta tgcccttaag gggtgacttg cctgagctct atcacctgag 1833

ctccccgtcc ctctggcttc ctgctgaggt cagggcattt cttatccctg ttccctctct 1893

gtctagggtgt catggttctg tgtaactgtg gctattctgt gtcctacac tacctggcta 1953

cccccttcca tggccccagc tctgcctaca ttctgattt tttttttttt ttttttttga 2013

aaagttaaaa attccttaat ttttattcc tggtaccact accacaattt acaggcaat 2073
 atacctgatg taatgaaaag aaaaagaaaa agacaaagct acaacagata aaagaccta 2133
 ggaatgtaca tctaattgac actacattgc attaatcaat agctgcactt tttgcaaact 2193
 gtggctatga cagtcctgaa caagaagggt ttcctgttta agctgcagta actttctga 2253
 ctatggatca tcgttcctt 2272

<210> 4
 <211> 352
 <212> PRT
 <213> Homo sapiens

<400> 4
 Met Thr Ser Ser Leu Leu Leu Ala Phe Leu Leu Leu Ala Pro Thr Thr
 1 5 10 15

Val Ala Thr Pro Arg Ala Gly Gly Gln Cys Pro Ala Cys Gly Gly Pro
 20 25 30

Thr Leu Glu Leu Glu Ser Gln Arg Glu Leu Leu Leu Asp Leu Ala Lys
 35 40 45

Arg Ser Ile Leu Asp Lys Leu His Leu Thr Gln Arg Pro Thr Leu Asn
 50 55 60

Arg Pro Val Ser Arg Ala Ala Leu Arg Thr Ala Leu Gln His Leu His
 65 70 75 80

Gly Val Pro Gln Gly Ala Leu Leu Glu Asp Asn Arg Glu Gln Glu Cys
 85 90 95

Glu Ile Ile Ser Phe Ala Glu Thr Gly Leu Ser Thr Ile Asn Gln Thr
 100 105 110

Arg Leu Asp Phe His Phe Ser Ser Asp Arg Thr Ala Gly Asp Arg Glu
 115 120 125

Val Gln Gln Ala Ser Leu Met Phe Phe Val Gln Leu Pro Ser Asn Thr
 130 135 140

Thr Trp Thr Leu Lys Val Arg Val Leu Val Leu Gly Pro His Asn Thr
 145 150 155 160

Asn Leu Thr Leu Ala Thr Gln Tyr Leu Leu Glu Val Asp Ala Ser Gly

165	170	175
-----	-----	-----

Trp His Gln Leu Pro Leu Gly Pro Glu Ala Gln Ala Ala Cys Ser Gln
 180 185 190

Gly His Leu Thr Leu Glu Leu Val Leu Glu Gly Gln Val Ala Gln Ser
 195 200 205

Ser Val Ile Leu Gly Gly Ala Ala His Arg Pro Phe Val Ala Ala Arg
 210 215 220

Val Arg Val Gly Gly Lys His Gln Ile His Arg Arg Gly Ile Asp Cys
 225 230 235 240

Gln Gly Gly Ser Arg Met Cys Cys Arg Gln Glu Phe Phe Val Asp Phe
 245 250 255

Arg Glu Ile Gly Trp His Asp Trp Ile Ile Gln Pro Glu Gly Tyr Ala
 260 265 270

Met Asn Phe Cys Ile Gly Gln Cys Pro Leu His Ile Ala Gly Met Pro
 275 280 285

Gly Ile Ala Ala Ser Phe His Thr Ala Val Leu Asn Leu Leu Lys Ala
 290 295 300

Asn Thr Ala Ala Gly Thr Thr Gly Gly Ser Xaa Cys Val Pro Thr
 305 310 315 320

Ala Arg Arg Pro Leu Ser Leu Leu Tyr Tyr Asp Arg Asp Ser Asn Ile
 325 330 335

Val Lys Thr Asp Ile Pro Asp Met Val Val Glu Ala Cys Gly Cys Ser
 340 345 350

<210> 5

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: mutagenic primer

<400> 5

ccacaccacc caccgcctgt gtgccccacgc

30

<210> 6
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: mutagenic primer

<400> 6
gcgtgggcac acaggcggtg ggtggtgtgg

30

<210> 7
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: mutagenic primer

<400> 7
ctggagggggg ctcagcctgt gtacccacgg

30

<210> 8
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: mutagenic primer

<400> 8
ccgtgggtac acaggctgag cccccctccag

30

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/07600

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/12 C07K14/495 A61K38/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, EMBASE, MEDLINE, CHEM ABS Data, BIOSIS, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HÜSKEN-HINDI, PETRA ET AL: "Monomeric activin A retains high receptor binding affinity but exhibits low biological activity." JOURNAL OF BIOLOGICAL CHEMISTRY, (1994) VOL. 269, NO. 30, PP. 19380-19384, 24 July 1994 (1994-07-24), XP002111996 the whole document	1-6,11, 13,14, 17,18,20
Y	—	7-10,12, 15,16, 19,21-35
	—	-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

14 December 2000

Date of mailing of the international search report

21/12/2000

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Hix, R

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP 00/07600

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AMATAYAKUL-CHANTLER, SUPAVADEE (1) ET AL: "(Ser-77)Transforming growth factor-beta-1: Selective biological activity and receptor binding in mink lung epithelial cells." JOURNAL OF BIOLOGICAL CHEMISTRY, (1994) VOL. 269, NO. 44, PP. 27687-27691, 4 November 1994 (1994-11-04), XP002111995 the whole document	1-6,11, 13,14, 17-22
Y		7-10,12, 15,16, 23-35
X	BRUNNER, AMY M. ET AL: "Site-directed mutagenesis of glycosylation sites in the transforming growth factor-beta-1 (TGF - beta -1) and TGF - beta -2 (414) precursors and of cysteine residues within mature TGF - beta -1: Effects on secretion and bioactivity." MOLECULAR ENDOCRINOLOGY, (1992) VOL. 6, NO. 10, PP. 1691-1700., XP000863262 the whole document	1-6,11, 13,14, 17,18,20
Y		7-10,12, 15,16, 19,21-35
X	BRUNNER A M ET AL: "SITE-DIRECTED MUTAGENESIS OF CYSTEINE RESIDUES IN THE PRO REGION OF THE TRANSFORMING GROWTH FACTOR BETA-1 PRECURSOR EXPRESSION AND CHARACTERIZATION OF MUTANT PROTEINS." J BIOL CHEM, (1989) 264 (23), 13660-13664., XP000857484 the whole document	1,3-6
Y	WO 94 17099 A (CELTRIX PHARMA) 4 August 1994 (1994-08-04) the whole document	1-35
Y	WO 95 04819 A (BIOPH BIOTECH ENTW PHARM GMBH) 16 February 1995 (1995-02-16) the whole document	1-35
Y	WO 96 01316 A (BIOPH BIOTECH ENTW PHARM GMBH ;HOETTEN GERTRUD (DE); NEIDHARDT HEL) 18 January 1996 (1996-01-18) the whole document	1-35
Y	WO 95 16035 A (GENETICS INST ;HARVARD COLLEGE (US)) 15 June 1995 (1995-06-15) the whole document	1-35
	-/-	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/07600

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 915 168 A (HOECHST MARION ROUSSEL LTD) 12 May 1999 (1999-05-12) the whole document	1-35
Y	WO 97 03188 A (BIOPH BIOTECH ENTW PHARM GMBH ;HOETTEN GERTRUD (DE); POHL JENS (DE) 30 January 1997 (1997-01-30) cited in the application the whole document	1-35
A	DAOPIN S ET AL: "CRYSTAL STRUCTURE OF TRANSFORMING GROWTH FACTOR-BETA2: UN UNUSUAL FOLD FOR THE SUPERFAMILY" SCIENCE, US, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 257, page 369-373 XP000857489 ISSN: 0036-8075 cited in the application the whole document	
A	M P SCHLUNEGGER ET AL: "An unusual feature revealed by the crystal structure at 2.2 Å resolution of human transforming growth factor-beta 2" NATURE, GB, MACMILLAN JOURNALS LTD. LONDON, vol. 358, no. 358, page 430-434-434 XP002110204 ISSN: 0028-0836 cited in the application the whole document	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP 00/07600

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9417099 A	04-08-1994	US 5420243 A AU 697916 B AU 4097797 A AU 685084 B AU 6093294 A CA 2153789 A DE 69424576 D EP 0791011 A ES 2146253 T JP 8510443 T US 5658883 A		30-05-1995 22-10-1998 08-01-1998 15-01-1998 15-08-1994 04-08-1994 21-06-2000 27-08-1997 01-08-2000 05-11-1996 19-08-1997
WO 9504819 A	16-02-1995	DE 4420157 A AT 189475 T AU 688362 B AU 7498694 A CA 2169171 A CN 1129013 A CZ 9600357 A DE 59409126 D DK 713529 T EP 0713529 A ES 2142953 T GR 3032628 T HU 74271 A JP 9501053 T NZ 271376 A PT 713529 T SI 713529 T US 5994094 A ZA 9405992 A		23-02-1995 15-02-2000 12-03-1998 28-02-1995 16-02-1995 14-08-1996 17-07-1996 09-03-2000 19-06-2000 29-05-1996 01-05-2000 31-05-2000 28-11-1996 04-02-1997 24-04-1997 30-06-2000 30-04-2000 30-11-1999 14-03-1995
WO 9601316 A	18-01-1996	DE 19511243 A AU 2979895 A CN 1151758 A DE 19580745 D JP 10502527 T US 6120760 A US 5807713 A ZA 9505444 A		04-01-1996 25-01-1996 11-06-1997 11-03-1999 10-03-1998 19-09-2000 15-09-1998 14-02-1996
WO 9516035 A	15-06-1995	US 6027919 A AU 689184 B AU 1301395 A CA 2176942 A EP 0733109 A FI 962350 A JP 9506261 T KR 249923 B NO 962304 A US 5658882 A		22-02-2000 26-03-1998 27-06-1995 15-06-1995 25-09-1996 16-07-1996 24-06-1997 15-03-2000 04-06-1996 19-08-1997
EP 0915168 A	12-05-1999	JP 9295945 A AU 2408497 A NO 985041 A CZ 9803449 A WO 9741250 A PL 329610 A		18-11-1997 19-11-1997 29-10-1998 17-03-1999 06-11-1997 29-03-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP 00/07600

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9703188 A	30-01-1997	DE	19525416 A	16-01-1997
		AU	6615196 A	10-02-1997
		EP	0837938 A	29-04-1998
		JP	11509097 T	17-08-1999

THIS PAGE BLANK (USPTO)
